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ABSTRACT OF DISSERTATION

PREVENTION OF HORMONAL MAMMARY-CARCINOGENESIS IN RATS BY
DIETARY BERRIES AND ELLAGIC ACID.

Breast cancer is the most frequently diagnosed cancer among women
around the world. The hormone 17ß-estradiol (E2) is strongly implicated as a
causative agent in this cancer. Since estrogen acts as a complete carcinogen,
agents that interfere with the carcinogenic actions of E2 are required. Most
agents effective against experimental mammary carcinogenesis have been
employed as pure compounds disregarding the synergy that exists between
several phytonutrients in a whole food. In these studies we have taken a unified
approach, by employing a pure phytonutrient – ellagic acid and whole foods that
contain the phytonutrient at various levels – berries, in the prevention of E2induced mammary cancer in ACI rats. We have also used a tiered approach by
screening several phytochemicals in vitro and implementing these results in both
short- and long-term studies. Initially, several phytochemicals were tested as
pure compounds against oxidative DNA damage induced by 4-hydroxy estradiol
and CuCl2. Ellagic acid, was the most effective agent (>98% reduction). In a
short-term in vivo study, both dietary blueberry and strawberry (5% w/w), were
ineffective in reducing the baseline oxidative DNA damage in the livers of CD-1
mice. However, red raspberry (5% w/w) was highly effective (50% reduction) and
ellagic acid (400 ppm) was moderately effective (25% reduction). Further both
diets up-regulated hepatic DNA repair genes in a similar fashion. In a long-term
estradiol-induced mammary carcinogenicity study in ACI rats, dietary berries
(2.5% w/w) and ellagic acid (400 ppm) reduced both tumor volume and tumors

per animal to different extents (50-75%). One mechanism by which these dietary
interventions inhibit mammary tumorigenesis may be via modulation of E2
metabolism, especially at the early stages of carcinogenesis. At 6 weeks after E2
treatment both berries and ellagic acid or berries alone significantly offset E2induced changes in CYP1B1 and CYP1A1 expressions respectively. In addition,
no toxicity or adverse effects are observed when rodents were fed either berries
(1 - 5%) or ellagic acid (400 ppm). These data taken collectively support the
possibility of using natural foods such as berries as an adjuvant to current
pharmacological therapies in the prevention and treatment of breast cancer.
Key words: Chemoprevention, Breast cancer, Berries, Ellagic acid, ACI rats.
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Chapter One: General introduction
Breast Cancer - Statistics
Breast cancer is the most prevalent cancer among women worldwide
(Parkin et al., 2005; Parkin & Fernandez, 2006). The global estimates of cancer
are provided by the International Agency for Research on Cancer (http://wwwdep.iarc.fr/globocan/database.htm). According to this, the global incidence of
cancer is estimated to be almost 11 million and the mortality and prevalence
figures are close to 7 and 25 million respectively (Parkin et al., 2005). Breast
cancer is the most frequent cancer contributing to 23% of all diagnosed cancers
in women. Among the 1.15 million cases diagnosed globally, 31.3% (230,000)
are in North America, which has the highest age-standardized incidence (99.4
per 100,000) (Table 1.1). Generally, it is seen that the incidence of breast cancer
is higher in developed countries compared to the developing nations (Figure 1.1),
which is attributed to combined influence of differences in lifestyle, hereditary
factors and screening practices, etc,. (Althuis et al., 2005). The mortality rate for
breast cancer is the fifth highest ranking behind lung, stomach, liver and colon
cancers. Breast cancer ranks as the most prevalent cancer among all cancers
(17.9%) due to its good prognosis. The average survival rates for women with
breast cancer are 73% and 57% for developed and developing nations
respectively (Parkin et al., 2005). The incidence and mortality of breast cancer in
the United States are 213,000 and 41,000 respectively (ACS, 2007a). The 5year survival rate after diagnosis of a localized breast cancer is 98%. Currently,
there are over 2 million breast cancer survivors in the United States (ACS,
2007b; ACS, 2007a). However, this survival rate varies with age, stage of tumor
at diagnosis, race/ethnicity and socioeconomic status of the patients (ACS,
2007b; ACS, 2007a). In Kentucky, over 3000 cases of breast cancer are
expected to be diagnosed, with a 20% mortality rate (ACS, 2007b; ACS, 2007a).
These global, national and regional statistics make breast cancer a primary
public health concern for women.
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Epidemiology
Epidemiology is the study of patterns, causes and control of a disease in a
given population. Epidemiological studies are of 3 types – (1) Retrospective or
case-control studies that look at the differences in risks between 2 populations
that are with (cases) and without (controls) a particular disease; (2) prospective
or cohort studies that involve study of outcomes of a particular disease in a given
set of population observed over a period of time; and (3) cross-sectional studies
that measure the prevalence of a disease in a particular population (Woodward,
2005).
Epidemiological

studies

of

breast

cancer

indicate

at

least

two

distinguishable types of breast cancer. About 10% of all breast cancers
diagnosed can be attributed to a familial or hereditary cause. Several genes have
been linked firmly to the disease and are discussed in some detail below.
However, about 90% of breast cancers diagnosed is termed as sporadic (Figure
1.2), which means that although there are several risk factors that elevate the
risk of developing the disease, one major cause cannot be singled out. Sporadic
cancer is thought to occur due to interactions between various risk factors.
The hereditary or familial breast cancer presents with germline mutations in
certain genes that are passed on from one generation to another. Certain
families or populations such as the Ashkenazi Jews, are at very high risk of
breast cancer due to the high prevalence of these genetic mutations (Brinton et
al., 2002; Thompson & Easton, 2004). Among these mutations, the most
common are the BRCA 1 and BRCA 2 mutations. These high-penetrance genes
are mutated in about 65% of all familial breast cancers diagnosed (Studzinski &
Harrison, 2002). The mutated gene produces an inactive protein that raises the
risk of ever having breast cancer from about 3% at age 30 to 85% at age 70
(Studzinski & Harrison, 2002). Specific mutations that are prevalent in up to 2.5%
of the Askenazi Jewish population have been identified (Studzinski & Harrison,
2002). The gene p53 is involved in cell-cycle arrest. Somatic mutations in this
gene are present in 50% of all cancers and about 15-30% of breast cancers.
2

However, germline mutations in this gene are rare and associated with the LiFraumeni syndrome, which presents with early onset tumors in multiple organs
including the breast. p53 mutations contributes to about 1% of all familial breast
cancer cases (Figure 1.2). Another such syndrome is Cowden’s syndrome with
germline mutations in the PTEN gene. More recently, mutations in the cell-cycle
check point gene-CHEK2 have been associated to familial breast cancer, not
linked to BRCA 1 or BRCA 2 mutations (Vahteristo et al., 2002; Oldenburg et al.,
2003; Thompson & Easton, 2004).
A great majority (90%) of breast cancer is considered sporadic since no
single risk factor can be clearly attributed to causation and is thought to be
caused by the interactions between multiple risk factors. Epidemiological studies
have linked several risk factors in the etiology of breast cancer. These risk
factors can be broadly classified into 3 categories (Table 1.2):
1. Non-modifiable risk factors such as age, gender, race/ethnicity, genetic
polymorphisms, familial history, and previous breast history.
2. Modifiable or lifestyle risk factors that include diet, exercise, body weight,
alcohol, and smoking.
3. Hormonal risk factors, including age at menarche and menopause,
parity, breast feeding, and hormone-replacement therapy (HRT).

Non-modifiable risk factors.
Age is considered the foremost non-modifiable risk factor for any cancer.
For women, the lifetime risk of developing cancer is slightly more than 1 in 3
(ACS, 2007b). Both the incidence and mortality due to breast cancer increase
with age, with the median age of diagnosis being 61 years (ACS, 2007a).
Women between the ages of 75 -79 have the highest incidence, while those from
20 to 24 have the lowest (ACS, 2007b). Women 50 and older have the highest
rate of both invasive cancers and carcinomas in-situ. Age also affects survival
and mortality trends after diagnosis. The rate of decline in mortality attributed to
better treatment was only 2% for women older than 50 compared to 3.3% for
3

those under (ACS, 2007b). Conversely, the 5 year survival rate is 89% for
women 40-74 compared to only 82% in those under 40. Female gender is a risk
factor by default. However, up to 1% of breast cancer occurs in males which are
usually linked to inherited traits (Studzinski & Harrison, 2002; ACS, 2007a).
It is known that African-American women have a lower incidence of breast
cancer than white women, but they are more likely to die of the disease at every
age (Bowen et al., 2006; Smigal et al., 2006). Other races and ethnicities have
recorded a much lower incidence rates. African-American women also have a
lower 5-year survival compared to Caucasians (76% versus 90%); this difference
is attributed to biological differences in cancer types, later stage at diagnosis,
poorer stage-specific survival, lack of disease awareness and socio-economic
reasons (Eley et al., 1994; Elledge et al., 1994; Klauber-DeMore et al., 2006).
Family history has been strongly linked to the incidence of breast cancer
in women. It is known that a woman’s risk increases linearly with the number of
first-degree relatives diagnosed (McPherson et al., 2000; ACS, 2007a). The
reason for this linkage is manifold, including genetic mutations that occur at a
very high rate in certain families, common environment, etc., (McPherson et al.,
2000; Mucci et al., 2001). Mutations in the Ataxia Telangiectasia gene has been
implicated in increased risk for breast cancer, although mutations in this gene by
itself do not seem to significantly increase breast cancer risk (Ellisen & Haber,
1998). Other genes that are inherited as germline mutations and may confer a
familial risk have been discussed earlier.
Other than the high-penetrance genes, genetic polymorphisms in several
low penetrance genes confer a small to moderate risk to carriers. Although their
risk-effect is low compared to high-penetrance genes, these variants are more
common in the general population and hence they confer a much higher
Population Attributable Risk (Nathanson & Weber, 2001). They include protooncogenes, tumor-suppressor genes and genes involved in cell-signaling, DNA
repair, carcinogen metabolism, etc., (de Jong et al., 2002). Such low penetrance
4

genes may play an important role in synergistically increasing the risk with an
environmental risk factor such as smoking (Dunning et al., 1999).
A woman’s breast history plays an important role in the etiology of breast
cancer. A benign proliferative change in the breast such as atypical hyperplasia
is associated with a four-fold increase in cancer risk later in life (Colditz et al.,
1993)). Other changes in the mammary epithelium are associated with a slight
non-significant increase in risk (McPherson et al., 2000).

Modifiable risk factors.
Diet is a very important modifiable risk factor. Diet is a complex mixture of
both carcinogens that enhance and protective factors that reduce risk. The role of
diet in both cancer causation and prevention is discussed in detail later.
Epidemiological studies have linked a high meat intake with increased breast
cancer risk (Cho et al., 2006). Indeed, chemicals present in meat such as
heterocyclic aromatic amines (HAA) and polycyclic aromatic hydrocarbons
(PAH), have been found to be carcinogenic in rodent models (Table 1.5)
(Huggins et al., 1961; Snyderwine et al., 1998). In addition, DNA adducts
presumably derived from these chemicals have been found in breast biopsies of
women diagnosed with breast cancer (Li et al., 1999), suggesting a causative link
between these dietary carcinogens and breast cancer. In addition to chemical
carcinogens, the role of dietary fat has been studied extensively in causation of
breast cancer. Although, several epidemiological studies showed a positive
correlation between high fat intake and breast cancer incidence (Hursting et al.,
1990; Cho et al., 2006), larger analyses of data suggest that there may be no
significant correlations (Smith-Warner et al., 2001; Wakai et al., 2005). However,
recent concerns regarding recall-bias of actual dietary intakes have been
reported (Prentice, 1996; Gonzalez, 2006a). If this is validated then re-analysis of
previously reported data may yet again yield different results. Nevertheless, key
risk factors, such as age at menarche, body weight and body fat content, are

5

influenced by diet and hence diet plays a key role in determining breast cancer
risk (Marchant, 1982).
Obesity is associated with a two-fold increase in the risk for breast cancer
in postmenopausal women (McPherson et al., 2000). Both adult weight gain and
increased waist to hip ratio are associated with increase in incidence risk
(Brekelmans, 2003; ACS, 2007a). For women with a Body Mass Index (BMI) >25
(Normal- 18-25) the mortality risk from breast cancer are 1.3 to 2.1- times higher
(ACS, 2007a). After menopause visceral fat stores are a major site for production
of estrogens, which reflects in the increased risk (Simpson et al., 1999; Lorincz &
Sukumar, 2006).
Regular physical activity has been shown to reduce the risk of breast
cancer among post-menopausal women (ACS, 2007a). This protective effect is
additive when present along with parity and a normal BMI (Thune et al., 1997).
Although the mechanisms are not well defined the effects are thought to be
induced by the effect of exercise on energy balance and hormones (Doll, 1996;
Bentz et al., 2005; McTiernan et al., 2006).
Alcohol consumption increases breast cancer risk. The consumption of
more than 24 g alcohol (two drinks a day) increases risk by 21% and there is a
dose-dependant correlation between alcohol intake and breast cancer risk
thereafter (Hamajima et al., 2002). Since alcohol consumption and smoking often
co-exist, it is seen that alcohol consumption can substantially confound the effect
of smoking on breast cancer (Hamajima et al., 2002). Alcohol is known to affect
the metabolism of steroid hormones and thus increase breast cancer risk
(Purohit, 2000; Singletary & Gapstur, 2001; Pierucci-Lagha et al., 2006).
The correlation between both active and passive smoking and breast
cancer remains inconclusive and highly debated. The report published by the
Collaborative Group on Hormonal factors in Breast Cancer, which looked at
60,000 cases and 100,000 controls, suggests that there is no association
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between smoking behaviors and breast cancer (Hamajima et al., 2002), although
there have been many smaller reports that contrast this (Chaturvedi, 2003).
However, recently a study published by Reynolds and coworkers suggest that
there are significant correlations between smoking and other lifestyle factors
(Reynolds et al., 2004). It was found that current-smokers tended to have a less
healthy lifestyle than non-smokers and hence may be more susceptible to the
effects of other risk factors. Associations between passive smoking and breast
cancer risk are inconclusive (Lee & Hamling, 2006).
Ionizing radiation is also known to increase the risk of breast cancer.
Studies among women exposed to nuclear radiation and also those exposed to
excessive x-ray radiation especially at a young age (Sigdestad et al., 2002),
suggests that there is a correlation between radiation and breast cancer.

Hormonal risk factors
The mammary glands are under the constant influence of several
hormones throughout the lifetime. Hence, hormonal factors play a major role in
the causation of breast cancer. The mammary gland is highly responsive to
hormonal influences. The developing mammary gland is under the endocrine
influence of organs such as the pituitary, the ovary and the adrenals
(Vonderhaar, 1988). In addition, the paracrine regulation by stromal cells is also
involved (Cunha & Hom, 1996; Wiseman & Werb, 2002). The mammary gland
development is, mostly but not exclusively, affected by 3 major hormones:
estrogen, progesterone and prolactin. Estrogen and progesterone play an
important role in the development of the mammary glands in non-parous women
(Anderson, 2002). Prolactin, secreted by the anterior pituitary, plays a significant
role in the development of the mammary gland during pregnancy and prior to
lactation (Kelly et al., 2002).
Estrogen is produced primarily by the ovaries in response to endocrine
stimulus from the pituitary (Jones & DeCherney, 2003). The mammary gland is
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constantly under the effect of estrogen. During each estrus cycle, the mammary
ducts undergo proliferative changes during the follicular phase when the
circulating levels of estrogen are higher (Schedin et al., 2000). Estrogen
exposure over lifetime is considered a significant risk factor for the development
of breast cancer (Lippman et al., 2001). This is supported by the increased
incidence of breast cancer in women with early menarche and/or late
menopause, resulting in a higher cumulative exposure to the ovarian hormone
(Hsieh et al., 1990). Also, women with serum estradiol levels in the highest tertile
(≥12 pmol/L) had a 2-fold higher risk of developing breast cancer than those in
the lower tertile (<12 pmol/L) (Lippman et al., 2001). Menarche and menopause
are determined both genetically and by environmental factors (Graber et al.,
1995; Petridou et al., 1996). The role of ovarian hormones in breast cancer risk
is further substantiated by the fact that women who have either uni- or bi-lateral
oophorectomy have a reduced risk of breast cancer, which directly implicates
ovarian hormones in the development of breast cancer (Parazzini et al., 1997).
Progesterone is another ovarian hormone that affects breast development.
Progesterone is mainly secreted during the luteal phase of the estrus cycle. The
link between exposure to endogenous progesterone and breast cancer has not
been clearly defined, however, the exposure to endogenous progesterone would
be proportional to the total number of menstrual cycles that a woman has in her
lifetime. There is some indication that the average serum progesterone levels
increases with age, but a correlation to breast cancer has not been established
(Garcia-Closas et al., 2002). Nevertheless, the link between exogenous
progesterone and breast cancer risk has been explored with regard to HRT.
Recent results from the Million Women Study, a study with the largest cohort as
yet, done in the UK, shows a clear association between HRT use and increased
breast cancer risk. They report that HRT increases the risk of both incident and
fatal breast cancer risk and that this risk is higher for a combination therapy of
estrogen and progesterone than for estrogen alone (Beral, 2003). This
corroborates an earlier finding by the Collaborative Group on Hormonal Factors
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in Breast Cancer (Lancet, 1997). Thus, progesterones may also be involved in
the development of breast cancer.
Prolactin, secreted by the anterior pituitary has a significant role in the
development of the mammary gland both before and during lactation (Topper &
Freeman, 1980). The undifferentiated lobules in the non-parous mammary gland
undergo both development and differentiation under the influence of prolactin
(Horseman, 1999). The reduced risk of breast cancer caused by parity can be
attributed to this differentiation. Breasts of parous women contain more
differentiated lobules (Lob 2 and 3) compared to non-parous women which
contain mostly undifferentiated structures (Russo et al., 2001). Indeed, an early
first full-term pregnancy is associated with a reduced risk of breast cancer as are
multiple pregnancies (Rosner et al., 1994). However, the protection decreases
with increasing age of first pregnancy. It is also seen that lactation is associated
with moderately reduced risk of breast cancer (Velie et al., 2005) .
It is clear that sporadic breast cancer arises due to interplay between
various risk factors. The hormonal milieu during a woman’s lifetime affects both
initiating as well as protective factors of breast carcinogenesis. To this end it is
required to explore in detail the effect of hormones on breast cancer
development and their interactions with other risk factors such as alcohol, body
weight and diet.
Hormonal control of mammary gland development.
In order to understand the role of hormones in cancer causation, it is
necessary to comprehend their role in the normal development of the mammary
gland. The mammary gland is highly complex tissue composed of different cell
types such as epithelial cells, stromal cells and adipocytes, that are both
dependant on and responsive to endocrine control throughout development
(Topper & Freeman, 1980). The role of cell-to-cell interactions, autocrine and
paracrine controls of growth are of paramount importance in this tissue. Most
studies on mammary gland development are based on rodent studies (Shyamala
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et al., 2002). The development of mammary gland occurs discontinuously
throughout lifetime, with major developmental stages being puberty, pregnancy
and lactation (Vonderhaar, 1988; Shyamala et al., 2002). At birth, the mammary
gland largely consists of rudimentary ducts consisting of a layer each of luminal
epithelial cells and myoepithelial cells surrounded primarily by connective tissue
(Vonderhaar, 1988). Initial development of the mammary gland takes place
during and after puberty (Vonderhaar, 1988). Puberty is marked by both a
dichotomous and sympodial growth and branching of the rudimentary ducts
(Russo et al., 2001). There is also a corresponding change in the stromal cells,
fat pads and other anatomical structures which contribute towards breast
development. With the initiation of menstrual cycles, the cyclic release of the
ovarian hormones imparts a gradual and constant growth in the mammary gland
(Vonderhaar, 1988; Shyamala et al., 2002). This proliferative process continues
until the age of 35 when it reaches a plateau (Russo et al., 2001).

The two

important ovarian hormones that affect breast development are estrogens and
progestins. The active forms of estrogens are estrone, estradiol and estriol and of
progestins are progesterone and 17-α hydroxy progesterone. The key effects of
various hormones on mammary gland development are summarized in table 1.3.
Estrogens are known to cause proliferation of the mammary epithelial cells
during each estrus cycle. After puberty, there is a gradual and extensive growth
of the mammary ducts under the monthly influence of estrogen (Shyamala et al.,
2000). At the end of puberty, around the age of 15, a woman’s breast consists
primarily of undifferentiated lobules type 1 (Lob 1) (reviewed in Russo et al.,
2001).

It is understood that many of these lobules do not undergo any

differentiation in non-parous women, making these a prone target for
transformation by carcinogens.
Much knowledge about the role of estrogen-receptors (ERs) in mammary
gland development has come from rodent studies involving estrogen-receptor α
null phenotype mice (αERKO) and others. Although a greater proportion of
actively dividing cells in the terminal end buds (TEB) have been found to be ER10

negative (Zeps et al., 1998; Russo et al., 2001), there is a small proportion of ERpositive luminal cells that seem to control growth and proliferation of others in a
paracrine fashion (Mueller et al., 2002; Shyamala et al., 2002). ERα is necessary
for normal ductal development (Bocchinfuso et al., 2000), its expression varies in
the different cell types and is down regulated by estrogen in normal cells
(Anderson, 2002; Shyamala et al., 2002). Also, the presence of ERα in both
stromal cells and epithelial cells are required for normal development, indicating
the importance of cell-to-cell communication and paracrine controls involved in
the development of mammary ductal structures (Mueller et al., 2002).
Progesterone predominates the luteal phase of the menstrual cycle and
plays an important role in mammary gland development. It primarily acts via 2
isoforms of its receptor PRA and PRB (Shyamala et al., 2000). These isoforms
are induced by estrogen (Shyamala et al., 2002), suggesting that actions of both
steroid hormones may be tightly coupled. It acts on cells already primed by
estrogen exposure to cause some maturational growth during each cycle. While
estrogen is considered important in the development of the ductal structure,
progesterone seems to play a role in the development of the lobulo-alveolar
structures, suggesting that it may play an important role in the differentiation of
the mammary epithelial cells (Shyamala, 1999). The ratio of the two isoforms
plays a major role in both normal mammary development as well as
carcinogenesis (Osborne et al., 2005).
Prolactin (PRL) is a peptide hormone secreted by the lactotrophs of the
anterior pituitary (Barrett, 2003). It is a 23 kdA protein that acts via its
transmembrane-receptor (PRLR) (Hennighausen et al., 1997). Prolactin affects
ductal

side

branching

and

TEB

regression

morphogenesis (Brisken et al., 1999) and

during

normal

mammary

during pregnancy causes

development of lobulo-alveolar structures involved in and for the post-partum
milk production (Hennighausen et al., 1997; Brisken et al., 1999). Apart from its
influence on the mammary gland, PRL also affects the ovary and the immune
system (Hennighausen et al., 1997).
11

Testosterone is the precursor hormone to estradiol and is converted to the
product by the enzyme aromatase. Although, the direct effect of testosterone on
mammary gland development is not clear, aromatase is a ubiquitous enzyme
found in many tissues, especially tissues most responsive to estradiol indicating
that testosterone plays an indirect role in mammary gland development
(Hinshelwood & Mendelson, 2001). It has been suggested that growth hormone
may indirectly affect ductal development during puberty via the stromal
compartment (Kelly et al., 2002; Wiseman & Werb, 2002).
In addition to the endocrine control, paracrine control by the stromal
compartment plays a prominent role in mammary gland development (Cunha et
al., 2004) and is mediated through the action of growth factors such as EGF,
TGF, IGF, CSF and MDGF etc., (Vonderhaar, 1988; Wiseman & Werb, 2002). It
is considered that these paracrine and intracrine effects of the stromal
compartment may play a critical role in breast carcinogenesis (Shekhar et al.,
2001; Wiseman & Werb, 2002).
Metabolomics of steroid hormones
To understand clearly the extent to which the human organism is
dependant on steroid hormones, one has to only look at the expression of steroid
receptors in the different organs. At least one type of ER can be found in every
organ in the body (Balfe et al., 2004). Also, several tissues in the body are
capable of synthesizing steroids, especially estrogen through de-novo synthesis
(Simpson, 2003). Hence, it is very important to know the metabolic pathways,
which include synthesis, activation and detoxification pathways of steroid
hormones to elucidate their role in a dysregulated state such as cancer. The
following section will discuss the metabolomics of primarily estradiol and to
smaller

extent

progesterone,

the

two

carcinogenesis.
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steroids

implicated

in

breast

The synthesis of 17ß-estradiol, the primary estrogen in the human body,
begins with the enzyme aromatase, which converts androgen precursors to
estrogens (Figure 1.3). In pre-menopausal women, this conversion occurs
primarily in the ovary, but to varying extents in other organs (Simpson et al.,
1994). However, in men and post-menopausal women, this conversion is the
primary source of estrogen for the various target tissues (Simpson, 2004). This is
supported by the presence of aromatase expression in several tissues in humans
and the highest aromatase expression among various mammalian species
(Bulun et al., 2005). The second pertinent enzyme, also expressed in all tissues
is 17ß-hydroxysteroid dehydrogenase (17ßHSD) that interconverts estrone and
estradiol. So far, 8 isozymes have been discovered and have specificities for
conversion between estrone and estradiol. Types 1, 3, 5 and 7 catalyze the
reduction of estrone to estradiol in the presence of nicotinamide adenine
dinucleotide phosphate (NADPH) as a cofactor and types 2, 4 , 8 in humans and
6 in rats catalyse the oxidative reaction using nicotinamide adenine dinucleotide
(NADH) as cofactor (Reviewed by Luu-The, 2001). In many ways this is also a
key enzyme as the presence of a particular isozyme decides the balance
between the levels of a weak and a strong estrogen. Estrogen-sulpho
transferases (EST) and estrogen sulphatases (STS) also take part in maintaining
a mobile pool of estradiol by catalyzing either the forward or the reverse
sulphonation reaction respectively (Sasano et al., 2006).
Estradiol is further activated via hydroxylation at various positions by the
phase I cytochrome P450 enzymes (Zhu & Conney, 1998). Of the different extrahepatic P450s important in estrogen metabolism, CYP1A1 and 1B1 are present
in the mammary and produce 2- and 4- hydroxy metabolites, known as
catechols, respectively (Zhu & Conney, 1998; Liehr, 2000). These hydroxylated
metabolites are further either glucuronidated (by UDP-glucuronosyl transferase),
methylated (by catechol-O-methyl transferase) or glutathione conjutated (by
glutathione-S-transferase), by the phase II enzymes (Zhu & Conney, 1998).
Several of the enzymes involved in the synthesis and metabolism of estradiol are
under its transcriptional control, via the ER pathway, indicating that estradiol can
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affect its production and removal (Beischlag & Perdew, 2005; Sissung et al.,
2006). The recent identification of differences in progesterone receptors as well
as metabolites, between the normal and tumor breast suggest that estradiol
metabolism may not be singularly responsible for mammary tumorigenesis
(Aupperlee et al., 2005; Wiebe et al., 2005).
Although the metabolism of steroids in the mammary is an important
aspect of the development of mammary carcinogenesis, the involvement of other
organ systems such as the liver, lung, kidney, adrenals, ovary and the pituitary,
all of which as involved in either steroid production, removal or signaling must be
taken in to consideration. It has to be stressed that changes in any of other organ
systems can set forth a domino-effect that can ultimately affect the breast.
Role of oxidative DNA damage in breast cancer
Oxygen plays a key role in the metabolism of a cell; it is the final
acceptor in the electron transport chain. Thus, cellular metabolism gives rise to a
set of highly reactive molecules known as the reactive oxygen species (ROS),
.

which include superoxide (O2-), singlet oxygen ( O), hydrogen peroxide (H2O2)
.

and hydroxyl radical ( OH) (Waris & Ahsan, 2006). ROS can cause damage to
cellular macromolecules such as DNA, RNA, proteins and lipids, altering their
structure and hence function. The cell has particular defense mechanisms to
protect itself against oxidative damage and the ultimate oxidative state of the cell
is dependant on the production and removal of ROS. Oxidative stress is caused
when there is a disruption in this balance. Both experimental and epidemiological
evidence suggests that oxidative stress plays an important role in the
development of many cancers including breast cancer. Several carcinogens are
known to be pro-oxidant (Morris & Seifter, 1992). Also, depletion of antioxidant
defense systems and induction of oxidative stress contributes to carcinogenesis
in experimental animal models (Van Remmen et al., 2003). Epidemiological risk
factors such as smoking, alcohol consumption, hormonal exposure, high fat
intake, etc., are known to indirectly increase oxidative stress (Ambrosone et al.,
2003).
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The key effects of oxidative stress on a cell can be summarized as
follows; damage to cellular macromolecules, alteration of cell signaling pathways,
and causation and maintenance of neoplastic changes. Oxidative DNA damage
includes oxidation of purine and pyrimidine bases, formation of abasic sites,
strand breaks and microsatellite instability (Cavalieri et al., 2000; Rizzati et al.,
2005). In case of proteins it results in altered function, and in case of lipids it may
cause a chain of lipid-peroxidative events. Lipid peroxidation end products such
and malondialdehyde (MDA) and 4-hydroxy-nonenol (4-HNE) can cause further
DNA damage (Bartsch & Nair, 2005).
The NF-ĸB pathway plays a central role in oxidative stress-mediated
changes in cellular signaling. It links several pathways that influence growth,
stress response, and apoptosis, hence is key to the survival of both normal and
cancer cells. ROS is an activator of NF-ĸB, which is found to be activated in
several transformed cell lines, primary and invasive tumors (Wu & Kral, 2005;
Biswas & Iglehart, 2006). Also, this pathway is associated with inflammation and
this can be activated by several cytokines (Bubici et al., 2006; Liu & Malik, 2006).
The downstream effects include increased transcriptional activation, increased
cell proliferation and evasion of apoptosis (Karin et al., 2002).
The oxidative stress induced by catechol-estrogen metabolites have been
implicated in estrogen-induced carcinogenesis (Yager, 2000). Either 17βestradiol alone or a combination of a strong oxidant (menadione) and weak
estrogen (ethinyl estradiol) induce renal cell carcinomas and increase the levels
of 8-iso-prostaglandin F2α, an oxidative-stress biomarker (Bhat et al., 2003).
Further reports that catechol-estrogens can cause oxidative DNA damage in vitro
in the presence of transition metal ions (Li et al., 1994; Hiraku et al., 2001; Aiyer
et al., 2002) designates a role for catechol-estrogens in inducing oxidative stress.
The oxidative status of the cell also dictates the progression stage of cancer.
Although, hypoxia is known to play a major role in angiogenesis and neovascularisation of the tumor, ROS signaling may play a role in the differentiation
of embryonic stem cells into a cardiovascular lineage which upon confrontation
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with tumor tissue may participate in tumor-related angiogenesis (Sauer &
Wartenberg, 2005). On the other hand, ROS has also been shown inhibitory to
tumor-related angiogenesis, probably via antagonism of hypoxia-inducibe factor
(HIF) pathway which is pro-angiogenic (Maxwell, 2005).

Multi-stage model of carcinogenesis
Carcinogenesis is a highly dynamic process by which normal cells are
transformed in to neoplastic cells. This involves an inducting event by a physical,
chemical or biological agent, subsequent transformation and clonal expansion
into a tumor, followed by angiogenesis and metastasis of the tumor (Pitot &
Dragan, 1991). The multi-stage model, which is a composite of many theories,
explains the process of carcinogenesis in the most comprehensive manner.
Although the development of cancer typically involves multiple steps, it can be
broadly classified in to 3 systematic stages and the study of the mechanism of
and interaction between these stages provides us with an opportunity to interrupt,
control and reverse the carcinogenic process (Figure 1.4). An initiating event
causes heritable genetic changes in the genome of a cell. This damage could be
caused by endogenous agents such as free radicals or exogenous carcinogens.
These genetic changes, which are irreversible, include gene mutations,
chromosome rearrangement, gene amplification and aneuploidy (Barrett, 1993).
Gene mutations can affect 2 key types of genes that control cell division and
death, the proto-oncogenes and the tumor-suppressor genes. Proto-oncogenes
are genes whose products allow for uncontrolled multiplication of a cell, while
tumor suppressor gene products check growth and are involved in apoptosis. In
a normal cell, the oncogenes are usually suppressed; a gain-of-function mutation
or hypomethylation activates these genes (Ehrlich, 2002). On the other hand a
loss-of-function mutation or hypermethylation is responsible for the suppression
of the normally active tumor suppressor gene (Jones & Laird, 1999).

It is

believed that both of these events must occur simultaneously for a cell to gain a
growth advantage (Knudson’s two-hit hypothesis) (Knudson, 2001). Although the
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two-hit hypothesis holds true for most cancers, it is often seen that multiple
genes (3-10) are mutated in most adult malignancies (Barrett, 1993).
Studies in chemical carcinogenesis delineate the role for metabolic
activation in the carcinogenicity of a given substance (Lijinsky, 1979).This further
lead to the classification of carcinogens as being either genotoxic or epigenetic
depending upon their action. Genotoxic carcinogens are those which either by
themselves or through their metabolites can induce karyotic changes
(Weisburger & Williams, 2000). Epigenetic carcinogens on the other hand cannot
induce genomic damage; however act in a growth enhancing manner on the
transformed cells (Pitot & Dragan, 1991).
In a comprehensive review, Hanahan and Weinberg (2000) discuss the
alterations and molecular mechanisms that initiated cells must undergo in order
to become malignant. To summarize, the promotional stage, usually defined as a
reversible stage in classic chemical carcinogenesis may involve evasion of
apoptosis and uninhibited cell growth in the presence of endogenous or
exogenous growth factors. As the neoplasm proceeds, the cells acquire self
sufficiency in growth and overcome inhibitory signals and immune surveillance,
followed by angiogenesis and invasion of host tissue. To paraphrase the authors,
tumor growth may be evolution gone awry.
It is necessary to apply the multi-stage model to breast carcinogenesis, as
this malignancy can be caused by an endogenous carcinogen (estrogen); may
involve activation of the carcinogen and other cellular and molecular changes
best explained by the current model. Also, this model provides us with the
opportunity to intervene at different stages to prevent, reverse or modify aberrant
changes with preventive agents.
Estrogen as a complete carcinogen
Of the risk factors associated with breast cancer, estrogen exposure has
the highest positive correlation to incidence. This is corroborated by 1) women
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with high serum levels of estradiol have a higher risk, 2) age at menarche and
menopause, which are correlates of cumulative estrogen exposure determine
risk , 3) removal of the ovary before or after breast cancer incidence results in a
more positive outcome, 4) high levels of tissue estradiol are found in breast
tumor biopsies, pointing to either accumulation or in-situ synthesis, 5) treatment
with anti-estrogens such as tamoxifen significantly reduces tumor recurrence .
Estrogen acts via 2 distinct pathways, both of which are equally important
for its carcinogenic activity. First, estrogen causes genotoxicity via its metabolic
pathway. Data for the support of this comes from numerous findings, extensively
reviewed by Liehr (Liehr, 2000; Liehr, 2001) and can be summarized as follows.
Pharmacological doses of estrogen induce renal-cell carcinomas in hamsters and
mammary adenocarcinomas in ACI rats in the absence of other carcinogens (Li
et al., 1983; Shull et al., 1997). Estradiol by itself can induce chromosomal
aberrations in cell culture similar to those seen in estrogen induced tumors
(Liehr, 2000; Li et al., 2002a). Catechol estrogens, which are active metabolites
of estrogen, can induce DNA damage causing both stable and unstable adducts
(Cavalieri et al., 2000; Liehr, 2000). Further, enzymes that convert estrogen to its
catechol metabolites, such as CYP1B1, are found in high levels in breast tumors
and microsomes from breast tumor tissues are known to metabolise estrogen to
potentially harmful catechols (Liehr & Ricci, 1996; Oyama et al., 2005). In
addition, polymorphisms that increase the metabolic activity of phase I enzymes
that activate and lower the activity of phase II enzymes that detoxify estrogen,
are known to increase breast cancer risk (Thompson & Ambrosone, 2000).
These facts evidence the importance of estrogen metabolism in the causation of
cancer.
The other important pathway crucial for estrogen carcinogenicity is its role
as a growth factor via steroid receptor signaling. The 2 types of estrogen
receptors- ERα and ERß have been extensively studied. Of these, ERα is
considered a diagnostic marker and an indicator of response to anti-estrogen
therapy, in breast cancer (Balfe et al., 2004). The mechanisms by which these
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receptors regulate cellular pathways in normal and malignant cells are numerous.
However, these can be broadly classified into direct transcriptional activation
after ligand binding and protein-protien interaction with other transcription
modulators, with or without ligand binding (Platet et al., 2004). Estrogen is
proliferative primarily through its action on ERα, which is also required for normal
development and differentiation of the mammary gland (Dickson & Stancel,
2000). The role of ERß as an inhibitor of this proliferative stimulus has been
explored leading to the conclusion the ERß may play a protective role in breast
cancer (Balfe et al., 2004; Paruthiyil et al., 2004). On the other hand, Russo and
colleagues have generated invasive characteristics in an ERα-/ERß+ cell line by
estrogen treatment (Russo et al., 2002). Further, it has been shown in vitro that
estrogen may inhibit invasiveness and the correlation that ERα+ tumors are less
invasive suggest that estrogen may play a protective role in breast cancer (Platet
et al., 2004). Also, the protein interactions of ERs have broad specificities and
are further controlled by intarcrine and paracrine signaling molecules (Cunha et
al., 2000; Simard & Gingras, 2001; Wiseman, 2005; Clarke, 2006). These facts
lead us to the conclusion that although the regulation of mammary tumorigenesis
by the estrogen is a highly complex process and estrogen has a high potential to
act as a complete carcinogen.
Role of diet in the causation and prevention of breast cancer
Diet is a complex mixture of both harmful and protective agents. The
balance between these agents can modify a woman’s risk for developing breast
cancer. A typical Western diet is predominantly high is animal products and low
in plant products (Cordain et al., 2005). Particularly, the post-industrial revolution
changes in both agricultural practices as well as food-processing methods have
given rise to a diet that leads to several chronic diseases, including cancer
(Cordain et al., 2005).
Several epidemiological studies have explored the association between
breast cancer risk and intake of foods such as red meat and high fat (BarrettConnor & Friedlander, 1993; Cho et al., 2003; Cho et al., 2006). Rodent studies
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have significantly implicated fats, a high percentage of calories from fat and
several red-meat carcinogens in the development of mammary cancer (Welsch,
1992; Snyderwine et al., 2002). Although for red-meat, epidemiological studies
corroborate experimental studies; for dietary fat, such associations are not clear
(Gonzalez, 2006b; Kim et al., 2006). However, there is concern about biases
and errors in methods used for recall such as the food frequency questionnaire
etc., which modify the outcome of such studies (Prentice, 1996; Gonzalez,
2006b). Thus, re-analysis of the same data after adjusting for these may as yet
yield different results. Also, increased red-meat intake is often associated with
higher intake of saturated fats (from animal sources) resulting in a synergistic
effect between the 2 risk factors. The method by which the food is cooked has a
profound effect on its nutritional value. High-temperature cooking of meats leads
to the pyrolysis and protein degradation products such as HAAs and polycyclic
aromatic hydrocarbons (PAHs), that are carcinogenic (Ferguson, 2002; Sinha,
2002; Snyderwine et al., 2002; Cross & Sinha, 2004).
The role of dietary factors in the prevention of various cancers has been
studied for several decades (Doll, 1996). Studies clearly indicate the protective
effects of fruits and vegetables in several cancers (Block et al., 1992; Helzlsouer
et al., 1994; Freudenheim et al., 1996). Furthermore, programs to promote
consumption of atleast 5 servings of fruits and vegetables a day both in the
United States and Europe strongly indicate the perceived protective effects of
fruits and vegetables against cancer and other chronic diseases (USDA, Web
resource; (Stanner, 2001).
The discovery of micronutrients and the effects of their deficiencies on
health in the early part of the 20th century lead to the hypothesis that the addition
of these micronutrients could potentially restore health (Underwood, 1998).
Subsequently, research on micronutrients such as vitamins E, C, and A (ßcarotene and retinoic acid), and selenium played a very important role in shaping
the next 2 decades in cancer prevention research (Shamberger, 1970; Cameron
et al., 1979; Niles, 2000; Hercberg, 2005). Historically, nutritional intervention in
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prevention of disease started with inhibition of vitamin deficiency diseases via
supplementation (Jukes, 1989). The concept of nutritional intervention in cancer
was conceived primarily by Peto and colleagues in 1980s. The observational
epidemiological studies until that time showed significant correlations between
lifestyle factors such as smoking, dietary fat, dietary fiber and fruit and vegetable
intake and disease risk. The idea that cancer could be prevented was introduced
by Sporn in 1976 with chemoprevention being defined as “the stabilization, arrest
and reversal of the progression of preneoplastic lesions” by either natural or
synthetic agents (Sporn, 1976). Thus the concept of preventing cancer using
dietary agents was ripe for application. The seminal paper by Peto et al., about
the applicability of beta-carotene in human trials set forth prospective randomized
intervention trials of various durations (Peto et al., 1981).
The two major clinical trials α-Tocopherol ß-Carotene prevention trial
(ATBC) in Finland and the ß-Carotene and Retinol efficacy trial (CARET) in the
US were started in the mid 1980s (Table 1.4). These were done in smokers with
an intervention dose of upto 30 mg ß-carotene and 25,000 IU of vitamin E
compared to a recommended intake of 1.8 mg and 22 IU, respectively for nonsmokers (RDI charts, USDA). Unexpectedly, the incidence of lung cancer in the
high–dose intervention groups was higher than placebo (Blumberg & Block,
1994; Forman et al., 2004). In a critical review, Block addresses several issues
that may have lead to the discrepancy between the observational and clinical
studies (Block, 1995). Certain important points worth noting are: first, most
clinical “prevention” trials are actually intervention trials and studied the effect of
mega-supplementation on already high-risk individuals; second, these trials
mostly concentrated on the effect of a single agent, whereas most
epidemiological study correlations are the result of interactions between several
food constituents; third, these trials abandoned the effect of life-style factors
before supplementation began, thereby discounting their effect on predisposition
to a chronic illness such as cancer. Although, clinical trials are important tools to
assess the efficacy of any intervention on a disease process, care needs to be
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taken while building a hypothesis around a multi-factorial, chronic (involving
several decades) disease such as cancer (Block, 1995).
There are about 25,000 known phytochemicals that have been identified
in the various foods that are consumed (Forman et al., 2004). In recent years due
to the concerted efforts of several analytical, molecular and synthetic chemists,
these are available in pure chemical forms to be tested in various experimental
systems. However, most of these agents will never be tested in pre-clinical or
clinical studies due to various complexities involved (Hercberg, 2005). Currently,
experimental evidence suggests that different chemicals may potentiate each
other in their anti-carcinogenic effects (Seeram et al., 2005). Epidemiological
evidence does not single out an agent that reduces the risk of cancer, although
the protective nature of fruits and vegetables in cancer is irrefutable (Block et al.,
1992; Block, 1995). Thus, a piece-meal approach to cancer prevention that has
lead to the failure of the 2 large intervention studies needs to be re-evaluated. As
discussed by Block, cancer is neither an infectious disease caused by a single
agent nor is it curable by a single pharmacological dose of one medication
(Block, 1995). Any research on cancer prevention must take this into account in
order to synthesize the right hypothesis as well as acquire effective results.
Estrogen-induced mammary tumors in ACI rats
Several in vitro experimental systems that simulate the mechanisms of
cancer development are often used to study the effectiveness of an agent or
drug. Since cancer is a whole-body process involving interactions between
several organ systems, the study of the effects on isolated tissues in culture will
not replicate the true effects of the drug (Clarke, 1996). Also, the study of
therapeutic affects of different agents in human subjects raises both economic
and ethical considerations (Clarke, 1996; Corpet & Pierre, 2005). Thus, the use
of animal models for study of carcinogenesis is imperative and unavoidable.
There are several advantages and disadvantages of using an animal model for
studying a process as complex as cancer. The advantages include control of
factors such as dose and duration of exposure, reduced interference from other
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environmental exposures, lower biological variability due to a higher homogeneity
in rodent populations as compared to humans, shorter lifespan of rodents, etc.
The limitations of various rodent models of breast cancer have been extensively
discussed by Kim et al., (2004). Although several rodent models of breast cancer
are available, none of them typically simulate the human conditions (Clarke,
1996; Gusterson et al., 1999; Kim et al., 2004). Nevertheless, these models are
very valuable for the purposes of testing intervention strategies and to
understand the molecular mechanisms that lead to breast cancer.
Breast tumors undergo progression from the in-situ stage through invasive
cancer to metastatic tumors (Clarke, 1996). Most animal models developed have
tried to replicate this development from one stage to the other as closely as
possible. The validity of most rodent tumor models has been derived based on
the similarities, both histopathological and molecular, between tumors of rodent
and human origin (Russo et al., 1990; Thompson & Singh, 2000). Although,
genetically engineered mouse models (transgenic and syngeneic) have
illuminated to a large extent molecular mechanisms involved in breast
tumorigenesis (Blackshear, 2001), their application in the treatment and
prevention of sporadic human breast cancer is limited (Clarke, 1996; Kim et al.,
2004). Also, explant models are less predictive of validity for translational
research (Gutmann et al., 2006).
The use of carcinogen-induced mammary tumors in rats as a preclinical
model has been popular for the past 4 decades. Table 1.5 highlights several
carcinogen- induced mammary tumor models currently available. There is
considerable heterogeneity in the incidence of mammary tumors in rats
depending on the rat strain used, type of carcinogen, time and mode of
carcinogen administration etc., (Huggins et al., 1959; Thompson et al., 1992;
Shepel & Gould, 1999). Strikingly, the most common feature among all these
models is that the disruption of the ovarian-endocrine axis by means of
ovariectomy affects the ability of carcinogens to induce mammary tumors
(Welsch, 1985; Shull et al., 1997; Thompson et al., 1998; Thordarson et al.,
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2001). This suggests that the development of mammary tumors shares at least
one common mechanism – ovarian hormone dependence.
The most commonly used carcinogen-induced mammary tumor models
are listed in Table 1.5. Synthetic chemical-carcinogens such as 7,12,
dimethylbenze[a]anthtacene (DMBA) or 1-nitroso-1-methyl urea (NMU) cause
high incidence of mammary tumors in treated rats compared to less than 50%
incidence with other carcinogens (Table 1.5). This makes the use of the DMBAand NMU- induced model most popular for study of mammary tumors. A single
intra-gastric dose of DMBA induces mammary tumors (Huggins et al., 1961).
However, not all induced tumors are adenocarcinomas and some tumors are
known to spontaneously regress (Haslam & Bern, 1977; Thompson & Sporn,
2002). Both in-situ and invasive carcinomas are induced by a single intraperitoneal or intra-venous dose of NMU (Gullino et al., 1975; Thompson et al.,
1992). These tumors appear to have an ovarian-independent phenotype in that
they can redevelop after initial regression following ovariaectomy (Thompson et
al., 1998; Thordarson et al., 2001). H-ras mutations commonly seen in
carcinogen-induced tumors are not present in humans (Sukumar et al., 1983;
Stanley, 1995; Gusterson et al., 1999). Also, genomic instability such as
anueploidy, which is a hallmark for human cancers, is rarely seen in chemicalcarcinogen induced tumors (Li et al., 2002a). Although such differences exist,
chemical-carcinogen induced mammary tumors have been extensively studied
and documented (Welsch, 1985; Russo et al., 1990).
In contrast to this, the interest in estrogen-induced mammary tumors in A
strain-Copenhagen-Irish hooded (ACI) rats, has waxed and waned since it was
first studied. The rat strain is unique in that they develop mammary
adenocarcinomas on exposure to estrogens. Initial interest in estrogen-induced
mammary tumors was seen in the 1930s and 40s with description of strain
differences in susceptibility to mammary tumors induced by different estrogens
(Noble et al., 1940; Dunning et al., 1947; Dunning et al., 1953; Noble & Cutts,
1959). Later, it was briefly revived by Shellabarger and coworkers in the late 70s
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and early 80s (Stone et al., 1979; Holtzman, 1988). Regardless of the type of
estrogen used (diethylstilbesterol (DES), estrone (E1), ethinyl estradiol (EE),
etc.,) ACI rats consistently develop mammary tumors, however they are resistant
to chemical-carcinogen induced tumors (Dunning et al., 1953; Cutts & Noble,
1964; Holtzman et al., 1979). The model used in this thesis was first described
by Shull and colleagues in 1997 and uses 27 mg of 17ß-estradiol (E2) in a
silastic implant delivered subcutaneously for the induction of mammary tumors
(Shull et al., 1997). Another variation developed by Li and colleagues uses 2-3
mg of E2 in 20 mg cholesterol pellets to induce mammary tumors (Li et al.,
2002a; Li & Li, 2003). In both models, the incidence of mammary tumors in
female ACI rats is 100% with a latency period of approximately 6 months.
Although, the exact molecular pathways involved are currently being discovered,
this model has a relative dearth of information compared with its DMBA-induced
counterpart. These shortcomings aside, the model affords an apt system for
testing preventive intervention.
Several key points support the use of this model to study breast cancer
prevention. First, estrogen is clearly and undisputedly associated with the
etiology of the disease in humans. Second, estrogen-induced tumors exhibit
chromosomal instabilities, which are also often seen in human breast cancer (Li
et al., 2002a; Li et al., 2004; Adamovic et al., 2007). Further, E2- and DMBAinduced carcinogenesis involves genetically distinct mechanisms (Schaffer et al.,
2006). Although these rats are susceptible to estrogen-induced prolactinomas,
the loci that control the pituitary and mammary tumor susceptibilities are
genetically distinct (Gould et al., 2004; Strecker et al., 2005; Schaffer et al.,
2006). In addition, the chromosomes that are affected in estrogen-induced
carcinogenesis are homologous to those that are affected in humans (Adamovic
et al., 2007). Finally, tumors display molecular markers such as an overexpression of cyclin D1 and c-myc, similar to breast cancer pathology in humans
(Weroha et al., 2006).
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Although some intervention studies were done in DES-induced mammary
tumor model, so far very few studies have looked at the effect of preventive
intervention in the estradiol-induced model (Petrek et al., 1985; Holtzman, 1988).
Of the few, a study by Shull and colleagues looked at hypo-caloric feeding and
prevention of mammary tumors (Harvell et al., 2002). Other studies include
prevention using Tamoxifen (Li et al., 2002b), phenobarbital (Mesia-Vela et al.,
2006) and a short term in vivo assay using diallyl sulphide (Green et al., 2005).
Collectively, these facts make the ACI rat model an ideal preclinical model for
exploring preventive intervention strategies which have a high applicability in the
translational setting.

Berries in cancer prevention
Berries are ideal agents for the chemoprevention of cancer. Figure 1.5
shows the pictures of and table 1.6 shows the nutritive value and total
anthocyanin content of some berries commonly consumed in the United States.
It is evident that berries are a good source of several chemopreventive nutrients,
including ß-carotene, selenium, vitamins A, C and E as well as phytonutrients
such as lutien, ellagic acid and anthocyanins (Table 1.6).
Ellagic acid, a polyphenol present abundantly in many berries is a known
chemopreventive agent. It has been shown to successfully reduce the incidence
and progression of carcinogen-induced tumors in the skin, lung, esophagus, liver
and colon, in rodents, when given orally (Reviewed by Stoner and Mukhtar,
1995). Several mechanisms such as antioxidant effect, modulation of
detoxification enzymes, regulation of cell cycle pathways, DNA binding and DNA
repair pathways have been attributed to this (Teel, 1986; Barch & Rundhaugen,
1994; Barch et al., 1994; Ahn et al., 1996; Chakraborty et al., 2004; Han et al.,
2006). Among the different berries, black raspberries have the highest ellagic
acid content and blueberries have the lowest (Table 1.6).
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Anthocyanins are flavanoids present in many fruits and is the source of
blue, red or purple color in plants (de Freitas & Mateus, 2006). Proanthocyanidins are polymers of anthocyanin molecules (Dixon et al., 2005). Both
are abundantly present in berries (Wu et al., 2004). Structures of anthocyanins
commonly found in berries are shown in Figure 1.6.

Dark berries such as

blueberries, blackberries and black raspberries have greater anthocyanin content
than their lighter counterparts (Wu & Prior, 2005; Wu et al., 2006).
Among the different berries, black raspberries have already been used in
a pilot clinical trial for the prevention of Barrett’s esophagus, a pre-disposing
condition for esophageal malignancy (Kresty et al., 2006). Bioavailability studies
on black raspberries prove that both ellagic acid and cyanidins are bio-available,
but excreted rapidly from the system (Stoner et al., 2005; Tian et al., 2006).
Several other bioavailability studies performed show that anthocyanins are highly
bioavailable, absorbed as such in the stomach or intestine and excreted with or
without methylation in the urine of both rodents and humans (McGhie et al.,
2003; Talavera et al., 2004; Tian et al., 2006).
Since, 17β-estradiol is highly implicated in breast cancer etiology,
targeting hormonal mechanisms is the best approach to prevention. Currently,
Tamoxifen is the leading preventive therapy for breast cancer. However,
treatment with Tamoxifen involves numerous adverse effects including increased
incidence of endometrial cancer, cataracts, and thromboembolism (Cano &
Hermenegildo, 2000; Morrow & Jordan, 2000). Although, Raloxifene was
equivalent to Tamoxifen in prevention of invasive breast cancer with fewer
adverse effects, thromboembolism, hot flashes and leg cramps are still possible
side effects (Cranney & Adachi, 2005; Jordan, 2006). In addition, Raloxifene is
poorly bioavailable and rapidly excreted, causing significantly reduced benefits in
women with poor compliance (Jordan, 2006). Nevertheless, the search for better
selective estrogen receptor modulators (SERMs) with fewer side effects is
ongoing (Jordan, 2006). The chemical structure of both anthocyanins and ellagic
acid is similar to estradiol (Figure 1.6). This similarity makes them ideal
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candidates for being SERMs. In fact, both ellagic acid and berry anthocyanins
show potent anti-estrogenic activities (Schmitt & Stopper, 2001; Papoutsi et al.,
2005; Larrosa et al., 2006). Further, the neuroprotective effects of blueberries are
thought to be mediated via antioxidant, anti-apoptotic and cell signaling
mechanisms involving extracellular signal-related kinase (ERK) and protein
kinase C (PKC) (Ramassamy, 2006). Incidentally, a pathway of estrogen-induced
ERK activation involves PKC in neural cells (Setalo et al., 2005). This implies that
blueberries may act via estrogenic mechanisms to provide neuroprotective
effects. These reports taken collectively vouch for the SERM effects of berries.
Thus, berries could be used by themselves or as an augmentative therapy
alongside other potent SERMs, in the prevention of breast cancer.
The failure of preventive trials with individual micronutrients has steered
the scientific community towards appreciating the interaction between bio-active
food components present in whole foods (Hampton, 2005; Meyskens & Szabo,
2005). Berries contain several such components (Table 1.6). Berries, such as
blueberries and black raspberries show high anti-oxidant activity (Wang & Lin,
2000; Wada & Ou, 2002). Black raspberries are known to affect inflammatory
cellular pathways such as COX-2, NF-қB involved in tumor progression (Chen et
al., 2006; Hecht et al., 2006). Both ellagic acid and berry extracts inhibit in vitro
proliferation of malignant cells through pro-apoptotic mechanisms (Seeram et al.,
2005; Han et al., 2006; Seeram et al., 2006). They also show anti-angiogenic
effects by regulating vascular endothelial growth factor (VEGF) pathway, thus
potentially affecting tumor metastasis (Losso et al., 2004; Labrecque et al., 2005;
Huang et al., 2006).
Since cancer is a multi-pathway disease, we need a multi-pronged
approach for the prevention of this disease. The case for the use of berries in
breast cancer prevention is strong because berries have been used for centuries
without adverse side effects (other than allergic reactions), their tolerability
studies are positive, their protective nutrients are highly bioavailable (Stoner et
al., 2005) and show anti-estrogenic, antioxidant, anti-inflammatory, anti28

angiogenic and pro-apoptotic activities that will be beneficial in cancer
prevention. As discussed earlier, estrogen acts as a complete carcinogen via
several molecular pathways, leading to breast tumor development. Berries are
the perfect multi-pronged tool to prevent breast cancer as they mediate
protection through multiple molecular pathways, several of which are also
affected by estradiol.

Hypothesis
I hypothesize that anthocyanins and ellagic acid, either individually or in
combination, will have a protective effect against estrogen-induced breast
cancer. To test this two different berries, one with a high-ellagic acid/highanthocyanin content, and other with low-ellagic acid/high-anthocyanin content,
and ellagic acid by itself will be provided via the diet to determine their potential
for inhibit 17ß-estradiol induced mammary tumors in ACI rats. The results of
these studies will have high translational value either to prevent or to augment
existing preventive therapy for breast cancer. The following specific aims will be
pursued to achieve my objectives
Specific Aims
1. To determine the in vitro antioxidant capacity of different polyphenols to
protect against catechol estrogen-induced oxidative DNA damage.
2. To employ dietary berries in a short-term in vivo study to determine the
protective biochemical effects.
3. To employ dietary berries of varying ellagic acid contents and ellagic acid,
in

an

estrogen-induced

mammary

tumor

model

to

study

their

chemopreventive potential.
4. To study the mechanisms by which dietary berries and ellagic acid cause
prevention of cancer in vivo.
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Figure 1.1. Age-standardized incidence and mortality rates for breast cancer per
100,000.
Source - Parkin, Bray , et al., 2005.
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Sporadic Breast cancer - 90%
Familial Breast cancer-10%
BRCA1/2-7%

Others-1%

p53-1%

Figure 1.2. Epidemiology of Breast Cancer.
Adapted from Charpentier and Aldaz, Humana Press Inc., 2000.
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17-OH-Pregenenolone
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17-OH-Progesterone

P450C17

P450C17
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3ß-HSD II
Dehydro
Androstedione
Testosterone
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Aromatase
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16- hydroxy metabolites
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GSTA1/M1
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Methoxy
conjugates

Glutathione
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Other
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Figure 1.3. Metabolomics of Steroid hormones- schematic showing the synthetic
and metabolic pathways of estradiol.
Adapted from Bulun et al., 2005.
Abbreviations: 3ß-HSD II- 3ß-hydroxysteroid dehydrogenase, type II; P450C1717α-hydroxylase; 17ßHSD I- 17ß-hydroxysteroid dehydrogenase, type I;
CYP1A1/1B1- Cytochrome P450 1A1/1B1; COMT- Catechol-O-methyl
transferase; GST-Glutathione-S-transferase; QR-NADP(H)-quinone reductase.
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Figure 1.4. Multistage model of Carcinogenesis and intervention strategies at
each stage.
Source- Forman et al., 2004.
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Figure 1.5. Pictures of berries commonly available in the United States.
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4-hydroxy-estradiol

Anthocyanin molecule
Anthocyanin
R1
R2
Pelargonidin (Pg) H
H
Cyanidin (Cy)
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Figure 1.6. Chemical structures of 17ß-estradiol, its metabolites and berryphytochemicals. The structural similarities that may be responsible for possible
estrogen-receptor binding of the various chemicals are highlighted. Table of
different functional groups in the anthocyanin molecule adapted from Wu and
Prior, 2005.
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Table 1.1. Crude and age-standardized (World) rates of Breast Cancer in
Northern America, per 100,000.

Country/Region
Northern
America
Canada
United States of
America

Incidence
Mortality
Prevalence
Crude
Crude
Cases
ASR (W) Deaths
ASR(W) 1-year
5-year
Rate
Rate
229,631 141.9 99.4

48239

29.8

19.2

230,990

1,058,170

19,540

53,05

33.7

21.1

19,590

89,439

42,913 29.4

19.0

211,400

96,8731

124.0 84.3

209,995 143.8 101.1

Abbreviations: ASR (W) – Age-standardized rate (World)
Source- GLOBOCAN 2002, International Agency for Research on Cancer.
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Table 1.2. List of risk factors for development of sporadic breast cancer.

Non-Modifiable
Risk Factors

Modifiable Risk
Factors

Hormonal Risk
Factors

Age

Diet

Cumulative exposure
to estrogen

Gender

Alcohol

Age at menarche and
menopause

Genetics

Smoking

Parity

Family History

Body Weight

Lactation

Previous Breast
Disease

Exercise

Hormone replacement
therapy

Radiation
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Table 1.3. Endocrine and paracrine control of mammary gland development
Hormone
Placental
Lactogens
Human
Chorionic
Gonadotropin
Estrogen
(Mostly via
ERα)
Progesterone

Prolactin

Androgens

Growth
Hormone

Paracrine
control

Stage of
development
Pregnancy
Pregnancy

Effect

Reference

Act Synergistically with
prolactin
Terminal differentiation
of mammary lobules

Forsyth, 1994

Post-natal
Ductal elongation and
(Primarily puberty proliferation
and pre-parous
period)
Lateral ductal branching
Post-natal
and lobulo alveolar
development
Post-natal
Ductal side branching
and TEB regression
Lobulo alveolar
Pregnancy
development via
JAK/STAT cell-signalling
pathway
Inhibition of epithelial
Fetal (especially
growth and nipple
in male fetus)
attachment in male fetus
by causing partial
necrosis of mammary
epithelium
Transformation of
Post-natal
mammary fibroblasts in
to preadipocytes which
then secrete PGE2 that
stimulates multiplication
of mammary epithelial
cells.
Mediated by growth
Mainly via the
factors such as TGF,
stromal
CSF-1, IGF-1, MDGF
compartment
and EGF.

Russo and Russo,
1995
Vonderhaar, 1988;
Shyamala, 2002;
Anderson, 2002
Shyamala, 2000

Brisken et al., 1999
Hennighausen et al,
1997; Brisken et al.,
1999; Kelly, et al.,
2002
Vonderhaar, 1988;
Houdebine , 1985

Houdebine, 1985;
Kelly et al., 2002.

Voderhaar, 1988;
Wiseman and Werb,
2002

Abbreviations: ERα-Estrogen receptor alpha; TEB- Terminal end bud; JAK-Janus
kinase; STAT-Signal tranducers and activators of transcription; PGE2Prostaglandin E2; TGF- Transforming growth factor; CSF- Colony stimulating
factor; IGF- Insulin like growth factor; MDGF-Macrophage-derived growth factor;
EGF- Epidermal growth factor.
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Table 1.4. Lung cancer prevention trials evaluating ß-carotene supplementation

Trial
ATBC
(Finland)

CARET
(United
States)

PHS I
(United
States)
WHS
(United
States)

Agent(s)
β-carotene(20 mg/d)
Vitamin E (50 mg/d)
(2 × 2 design)

Population
Male smokers
50–69 yr
(μ = 57 yr)
36 years of
smoking
β-carotene (30 mg/d) Male and female
Retinyl P. (25,000 IU) Smokers
(μ = 58 yr)
(2 × 2 design)
49 years of
smoking

N
29133

F/U
5–8 yr
μ = 6 yr

Risk effect
876 cases
RR = 1.18 (1.03, 1.36)

18314

4–7 yr
μ = 4 yr

286 cases
RR = 1.36 (1.07–1.73)
β-Carotene suppl.

Male MDs
age 40–84
11% smokers
Females
β-carotene
(50 mg/alternate/d) of age 45 +
13% smokers
8 groups

22071

12 yr

39876

2.1 yr

β-carotene
(50 mg/alternate d)

14254

RR = 1.28 (1.04, 1.57)
β-Carotene+ Retinyl P.
82 cases in β-Carotene
88 cases in placebo
RR = 0.98 (0.91- 1.06)
30 cases in β-carotene
21 in placebo

Abbreviations: ATBC- Alpha-Tocopherol β-Carotene Trial; CARET- Carotenoid
and Retinol Efficacy Trial; PHS- Physicians' Health Study; RR- relative risk;
WHS- Women's Health Study; F/U-years of follow-up during the trial; N- number
randomized; µ- mean; Retinyl P- Retinyl Palmitate. All trials were designed as
randomized controlled trials.
Source- Forman et al., 2004
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Table 1.5. Rat models of carcinogen-induced mammary tumors.

Rat
strain

Carcinogen
2-AAF
3-MC

Age at
induction
50 days

DMBA

PO

%
Incidence
30%

Latency
(weeks)
8

PO
PO

100%
100%

7.3 ± 2
6.1 ± 1

100%

10 ± 2

Dose

Route

100 mg
100 mg
20mg

DMBA

48 days
SD

1µM per
IM
gland

DB[a, l ]P

B[a]P

45 days

50 mg/kg
body
weight
75 mg/kg
body
weight
2 or 3
mg
27 mg

36-49 days

9 mg

NMU

50 days

PhIP

43 days
49 days

ACI

17ßestradiol

IP

100%

11 ± 1

45%

22 ± 1

100%

8

PO
24%
-10
doses

NR

SC-P

100%

NR

SC-T

100%

21 ± 3

SC-T

100%

NR

Tumor type
Carcinoma
Carcinoma
Carcinoma
Adenocarcinoma
(62%)
Fibroadenoma
(6%)
Fibrosarcoma
(28%)
Adenocarcinoma
(83%)
Fibroadenoma
(0%)
Fibrosarcoma
(16%)
Fibrosarcoma
In situ and
invasive
carcinoma
Carcinoma

Reference
Huggins et al.,
1961

Cavalieri et al.,
1991

Thordarson et al.,
2001
Snyderwine et al.,
1998
Li et al., 2002

In situ
carcinoma

Shull et al., 1997
Ravoori et al.,
2007

Abbreviations: 2-AAF- 2-acetylaminofluorine; 3-MC- 3-methylcholantherene;
DMBA- 7,12-dimethylbenz(a)antharcene; DB[a,l]P-dibenzo[a,l]pyrene;
B[a]P-Benzo[a]pyrene; NMU- 1-methyl-1-nitrosourea; PhIP-2-amino-1-methyl-6phenylimidazo[4,5-b]pyridine; SD- Sprague Dawley; ACI- August-CopenhagenIrish-hooded; NR-Not reported.
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Table 1.6. Nutrient composition of commonly available berries

Nutrient

Units/
100g
fresh
weight

Strawberries Blueberries Cranberries
Vaccinium
Vaccinium
Fragaria
macrocarpon
Spp.
Ananassa

Ellagic acid*

mg

91
32
0.70
0.30
2.0
16
4.4
12
59
0.29
7
26
21a
6.3b

ORAC value

µmoles/
TE/g

21d

Water

g

Energy

Kcal

Protein

g

Total Fat

g

Total dietary Fiber

g

Calcium

mg

Selenium

µg

Vitamin A

IU

Vitamin C

mg

Vitamin E

mg

β-Carotene

µg

Lutein

µg

Total anthocyanin

mg

Blackberries
Rubus Spp

Red
raspberries
Rubus idaeus

Black
raspberries
Rubus
occidentalis

84
57
0.7
0.33
2.4
6
0.1
54
10
0.57
32
80
386a
<1.0b

87
46
0.4
0.13
4.6
8
0.1
60
13.3
1.2
36
91
140a
1.2b

88
43
1.4
0.50
5.3
29
0.4
214
21
1.17
128
118
245a
15b

86
52
1.2
0.65
6.5
25
0.2
33
26
0.87
12
136
92a
33.9c

86a
72c
1.4c
0.14c
1.7c
32c
NA
38c
2.4c
NA
NA
NA
687a
53.7c

60e

95e

56e

21d

77f

Source: USDA National Nutrient Database except where mentioned.
a- Information from Wu et al., 2006.
b- Information from Daniel et al., 1989.
c- Information from Oregon Berry Commission.
d- Information from Kalt et a.l, 1999.
e- Information from Wu et al., 2004
f- Information from Wada and Ou, 2002.
Abbreviations: ORAC- Oxygen Radical Absorbance Capacity; NA- Information
not available; TE-Tocopherol Equivalents.
Copyright © Harini Sankaran Aiyer, 2007
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Chapter Two: Effect of phytonutrients (pure compounds) and whole food
(berries) on DNA damage and gene expression.

Introduction
Female hormone - 17β-estradiol (E2) is associated with the etiology of
breast cancer, which is the second leading cause of cancer-related death in
American women (Russo et al., 2000; ACS, 2007). It has been shown that E2 and
its metabolites can lead to mutations by increasing the rate of DNA damage as
well as decreasing DNA repair (Russo et al., 2000; Mailander et al., 2006).
Metabolites of E2 such as 2- and 4-hydroxy estradiol (4E2), can cause oxidative
DNA damage in the presence of Cu2+ (Li et al., 1994; Yager, 2000). Since
oxidative DNA damage can ultimately lead to further downstream detrimental
effects, effective inhibition of this damage may be a useful prevention strategy.
There are several methods available to assess DNA damage. Among
these, ones that combine a chromatographic method with mass spectrometry
have been used to measure numerous products at the same time (Dizdaroglu et
al., 2002). Also,
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P-postlabeling in conjunction with thin layer chromatography

(TLC), can be used to measure oxidative DNA damage of various DNA bases,
including the benchmark oxidative lesion 8-oxo-2’-deoxyguonosine (8-oxodG)
(Gupta & Arif, 2001; Gupta et al., 2003; Ravoori et al., 2006). Recently, we have
discovered several polar DNA adducts by
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P-postlabeling and low salt

chromatography. Chromatographic comparison with oxidative DNA adducts
formed by Fenton-type reaction (Cu2+-H2O2) suggest that some of the polar
tissue adducts may be oxidative adducts (Aiyer et al., 2003; Gupta et al., 2003).
These adducts can be used as a biomarker for selection of antioxidant agents
that can modulate DNA damage. Earlier studies from our laboratory have
successfully used detection of DNA damage in conjunction with a cell-free
system to rapidly screen for chemopreventive/antioxidant agents, thus expediting
the process of agent selection (Smith & Gupta, 1999; Srinivasan et al., 2002). In
cancer prevention, a tiered preclinical approach involves screening of several
potential preventive agents in cell-culture and rodents prior to their use in clinical
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trials. We have been successful in using this tiered approach in reducing benzo[a]-pyrene-induced DNA damage. Agents such as oltipraz and ellagic acid that
were effective in an enzymatic cell-free system were effective in both cell-culture
and in vivo (Smith & Gupta, 1999; Smith et al., 2001a; Smith et al., 2001b). This
tiered approach can be used successfully in the selection of agents that would be
effective in long-term studies without having the need for employing several
compounds in expensive long-term in vivo studies.
There are several surrogate biomarkers available to assess the efficacy of
dietary agents on a biological system. Among these, the liver due to its proximity
and role in the first-pass mechanism represents a suitable surrogate tissue. In
addition, due to its high metabolic activity, liver is constantly exposed to the
oxidative by-products of cell metabolism, thus making it an ideal tissue to assess
the modulation of baseline oxidative DNA damage by dietary agents.
A significant epidemiological association between fruit and vegetable
intake and low cancer incidence has been reported (Block et al., 1992).
Flavonoids are low molecular weight compounds present ubiquitously in plants.
They have a common 3-ring structure with various substituents which make them
structurally diverse. Many of them have significant biological effects which
include favorable metabolism of xenobiotics, antioxidant properties, and effects
on cell-signaling that make them desirable candidates for cancer prevention
(Reviewed by Middleton, Kandaswami and Theoharides, 2000).
In this study, we have used a 2-tiered strategy to initially test more than 10
flavonoids in an in vitro test system and employ the most effective agent in a
short-term in vivo study. The test agents selected were either well known
flavonoids (ellagic acid, epigallocatechin gallate (EGCG), quercetin) or other less
known compounds (naringenin, ferulic acid etc.,). Ascorbic acid and vitamin E
were included as known antioxidants. The most efficacious agent in this tier was
ellagic acid, which was tested in a short-term in vivo study as a dietary
chemopreventive agent. Whole foods (berries) containing significant levels of
ellagic acid were also provided via diet to compare the bioavailability and efficacy
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of ellagic acid given as a pure compound and in whole food. The modulation of
oxidative DNA damage in both systems was assessed by
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P-postlabeling/TLC.

In addition, the possible mechanisms by which these agents modulate DNA
damage in vivo were explored by gene-expression analyses using microarray
technology.
Materials and Methods
Chemicals. Ascorbic acid, biochanin and ferulic acid were purchased
from Aldrich Chemical Company (Milwaukee, MI)., Ellagic acid,

naringenin,

resveratrol, silymarin, quercetin, α-tocopherol, acetone, dimethyl sulfoxide
(DMSO) and salmon testes DNA (st-DNA) were purchased from Sigma Chemical
Company (St. Louis, MO). Epigallocatechin gallate was purchased from LKT labs
(St. Paul, MN). 4-hydroxy estradiol (4E2) was purchased from Steraloids Inc.
(Newport, RI). Chemicals involved in
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P-postlabeling were purchased from

sources described earlier (Gupta, 1996). All chemicals used were > 95% pure
and were used without further purification. Salmon testes (st)-DNA was further
purified before use, as described previously (Gupta, 1996).
Induction of DNA damage by 4E2/CuCl2. Salmon testes-DNA (300
µg/ml) in 10 mM Tris Hcl, pH 7.4, was pre-incubated with vehicle alone and the
test agents dissolved in either DMSO or acetone (≤ 5% each) and CuCl2 (100
µM) for 15 min at 37ºC. Redox-cycling was initiated by the addition of 4E2 (100
µM) in ethanol. After incubation at 37°C for 1h, DNA was purified by solventextraction and ethanol precipitation as described (Gupta, 1996; Ravoori et al.,
2006).
Animals and diet. Eight week-old female CD-1 mice were purchased
from Harlan-Sprague Dawley (Indianapolis, IN). CD-1 mice were chosen as an
exploratory model for estrogen-induced carcinogenesis as these animas are
highly susceptible to estrogen-induced uterine cancer (Newbold and Liehr, 2000).
Five groups (n=6) were fed ad libitum, either a control diet or diet supplemented
44

5% (w/w) with strawberries, blueberries, red raspberries or 400 ppm ellagic acid,
according to the protocol (Figure 2.1). Three berries with low (blueberries; < 100
ppm), moderate (Strawberries; 500 ppm) and high (raspberries; 1500 ppm)
ellagic acid content were chosen (Daniel et al., 1989). The ellagic acid dose was
selected based on a similar short-term study in rats (Ahn et al., 1996). Organic
blueberries, strawberries and non-organic raspberries were purchased as fresh
produce locally (Lexington, KY). All berries were dehydrated in a food
dehydrator, powdered, vacuum dried to remove remaining moisture, sealed
airtight in zip-top bags and stored at -80°C until use. Ingredients for the diet were
purchased individually from Dyets, Inc. (Bethlehem, PA). The control diet was
slightly modified from the original composition for the AIN-93M diet (Reeves et
al., 1993) such that the carbohydrate calories were provided by corn starch and
dextrose without the inclusion of sucrose (Table 2.1). The dried berries were
added along with various ingredients at 5% (w/w) of the modified control diet and
mixed in a Hobart mixer until homogenous. The corn starch component of the
diet was adjusted in these diets such that all diets were isocaloric after
supplementation with berries. Ellagic acid was added at 400 ppm without any
adjustment to the diet and mixed as described. These diets were stored at 4°C
until use. Animals and the diets were weighed weekly to assess differences in
diet intake and weight gain. They were euthanized by CO2-asphyxiation at the
end of 3 weeks and liver was snap-frozen using liquid nitrogen in 2 aliquots,
which were used for 32P-labeling and microarray analysis respectively.

Analysis of polar oxidative DNA adducts by 32P-postlabeling/TLC.
DNA from liver was isolated as described (Gupta, 1996). Briefly, the tissue was
homogenized in TE buffer (50 mM Tris-HCl/10 mM EDTA, pH 8.0) and the
nuclear pellet was sequentially treated with RNases (RNase A-150 µg/ml, RNase
T1-1 U/µl) and proteinase K (150 µg/ml), followed by solvent extraction and
ethanol precipitation. The resultant DNA pellet was washed with 70% ethanol
and dissolved in HPLC water. After shearing, the DNA concentration was
measured spectrometrically considering 1A260= 40 µg. Fourteen µg was digested
to 3’-monophosphates using micrococcal nuclease/spleen phospodiesterase
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(Enzyme: DNA – 1:5, 5h, 37ºC). After removing 2 µg of digest for normal
nucleotide analysis, 10 µg digest was enriched for novel oxidative adducts by
treatment with nuclease P1 (E: S-1:2.5, 1h, 37ºC). Remaining 2 µg of the digest
was enriched for 8-oxodG by polyethyleneimine (PEI)-cellulose TLC and 0.5-1µg
was labeled as described (Gupta & Arif, 2001). The 5’-32P-labeling of both
enriched DNA adducts and normal nucleotides were done in parallel, using T4polynucleotide kinase in a molar excess of [γ-32P] ATP as described earlier
(Gupta, 1996; Ravoori et al., 2006). Labeled adducts were separated using 2
directional PEI-cellulose TLC using 50 mM sodium phosphate, pH 6.0 and 1 M
formic acid in the D1 direction. D2 was perpendicular to D1 using a solvent
containing 2 M urea, 2.8 M Ammonium hydroxide and 50% isopropanol. Adducts
with decreasing polarities in tissue DNA were eluted by increasing the sodium
phosphate concentrations (50 mM – 1,000 mM) in the presence of 1M formic
acid (D1) but maintaining the same D2 solvent. Adducts and normal nucleotides
were visualized using Packard Instant Imager and were counted individually. The
enriched 8-oxodGp was labeled in parallel and chromatographed as described
(Gupta & Arif, 2001). Adduct levels were calculated as relative adduct labeling
(RAL) = (CPM adducted nucleotides/CPM normal nucleotides) X 1/dilution factor
and are expressed as adducts/106 nucleotides (in vitro adducts) and adducts/109
nucleotides ( in vivo adducts).
Gene expression analysis. RNA was isolated using the phenol:
chloroform extraction followed by DNase treatment. cDNA probes were
synthesized from poly A+ RNA, using [α-32P]- ATP (3000 Ci/mmol). These probes
were then hybridized to AtlasTM nylon mouse stress array overnight. Following
hybridization the membrane was exposed to x-ray film. The obtained
autoradiographic images were then scanned with a MicroTek ScanMakerIII flatbed scanner and then subjected to densitometric analysis using ArrayExplorer©
to extract the gene intensities (Patriotis et al., 2001). The data was normalized,
using linear regression analysis. The gene expression profiles were estimated as
log2 of the ratio of the gene intensities of the control diet vs. supplemented diet.
The genes with significant down- or up-regulation were identified. These
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analyses was performed in Dr.Margie Clapper’s laboratory at the Fox Chase
Cancer Center (Philadelphia, PA) and the data was presented under joint
authorship at the 95th annual meeting of the American Association for Cancer
Research (Aiyer et al., 2003). Further this chapter was reviewed by Dr. Clapper
and approved to be submitted (personal communication dated 3-31-07).
Statistics. The adduct levels for each test agent was compared to the
level of its respective vehicle control using Dunnet’s two-sided t-test. A Scheffe’s
t-test was used for comparing dose response studies. A p-value <0.05 was
considered to be statistically significant. The results are expressed as mean ±
SE.
Results
Modulation

of

4E2/CuCl2-induced

oxidative

DNA

adducts

by

phytonutrients. Analysis of DNA damage, induced by redox cycling of 4E2 in the
presence of Cu2+, revealed several unidentified polar adducts and 8-oxodG
(Figure 2.2 A1-B4). These were chromatographically similar to adducts
generated by treatment of DNA with H2O2 /CuCl2 (Srinivasan et al., 2001).
Neither 4E2 nor Cu2+ by themselves increased the levels of these adducts from
baseline (data not shown). The level of unidentified polar adducts and 8-oxodG in
the untreated st-DNA were 9.73 ± 0.03 /106N and 11.5 ± 0.85 /106N, respectively,
and this increased to 985 ± 54/106N and 1349 ± 189/106N after treatment with
100 µM each of 4E2 and CuCl2.
All agents were tested initially at a final concentration of 300 µM, based on
earlier studies (Smith & Gupta, 1999; Srinivasan et al., 2002). In the initial
screening, ellagic acid was the most effective showing >95% reduction of both
unidentified oxidative adducts and 8-oxodG compared to the vehicle control (Fig
2.2 A3, B3; Figure 2.3, p<0.05). This agent also showed a dose-dependant
modulation of DNA damage starting at a concentration of 30 µM (Figure 2.4,
p<0.005). Other flavonoids such as resveratrol, quercetin and naringenin showed
only moderate reduction (Figure 2.3), while some other agents such as silymarin,
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and EGCG showed an increase in DNA damage. (Figure 2.3; p<0.05). Known
antioxidants, namely vitamin E and ascorbic acid showed moderate reduction
and pro-oxidant effects respectively (Figure 2.3). Based on these results, ellagic
acid was selected for a short-term in vivo study.

Modulation of baseline oxidative-DNA damage by ellagic acid and
berries. There was no significant difference in the diet intake or weight gain
between the groups (Figure 2.5 A and B). No toxicity or weight loss was
observed at doses tested. All groups represented qualitatively similar adduct
pattern (Figure 2.6-Inset). The baseline levels of different subgroups of adducts
in the liver of mice fed control diet were: P-1 – 3800 ± 1870; P-2- 2600 ± 1320;
PL-1 – 180 ± 72 and L-1 – 2600 ± 1340 per 109 nucleotides. PL-2 adducts were
too low to be quantified and 8-oxodG, PL-3 and L-2 adducts were not analyzed.
In this study, red raspberry diet reduced all subgroups of adducts analyzed
effectively, with a 50% reduction of P-1 adducts, 60% reduction of P-2 adducts,
50% reduction of PL-1 adducts and a 30% reduction of L-1 adducts (Figure 2.6).
Ellagic acid showed similar effects albeit at a lower level with 30% reduction in P1 adducts, 45% reduction in P-2 adducts, 50% reduction in PL-1 adducts and no
effect on L-1 adducts. Blueberry diet only reduced the L-1 adducts (30%) and
had no effect on other adduct subgroups. Strawberry diet was ineffective in
altering any subgroup of adducts (Figure 2.6).

Modulation of gene expression by red raspberry and ellagic acid
diets. Following the similar modulation of adduct patterns by both red raspberry
and ellagic acid diets, limited gene expression analysis was done to determine
effect of the intervention on genes involved in DNA repair and xenobiotic
metabolism. Microarray analysis revealed that several genes were modulated in
a similar fashion by both diets. In particular, genes involved with DNA repair such
as – xeroderma pigmentosum group A complementing protein (XPA), DNA ligase
III (DNL3), DNA excision repair protein ERCC1- were found to be over-expressed
by 3 to 8 fold (Figure 2.7A and B). There was a significant similarity in the
number of genes over- or under-expressed by both diets (Figure 2.7). Red
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raspberry diet down-regulated genes such as Mitogen activated protein kinase
14 (MAPK14) and MAP kinase kinase (MAPKK), involved in key cell-signaling
pathways, by >15 fold.
Discussion
The induction of oxidative DNA damage by 4E2 in the presence of
Cu2+ is postulated to involve hydroxyl radicals (Hiraku et al., 2001). The
qualitative presentation of polar adducts generated using either 4E2/CuCl2 or
H2O2/CuCl2 is similar (Srinivasan et al., 2001; Aiyer et al., 2002). Also, cochromatography studies with oxidative DNA adducts from H2O2/CuCl2 show that
polar adducts generated from 4E2/CuCl2 may be generated in part via oxidative
mechanisms (Gupta et al., 2003). Several studies indicate that H2O2/Cu2+ as well
as

Cu+/Cu2+ redox cycling is involved in the generation of reactive oxygen

species (ROS) by 4E2 (Oikawa et al., 2001; Frelon et al., 2003). The results of
this study correlates well with earlier studies on reduction of 8-oxodG induced by
H2O2/CuCl2 by ellagic acid (Srinivasan et al., 2002). The trend in induction of
both unidentified oxidative adducts and 8-oxodG were similar, but the absolute
levels of 8-oxodG was higher after 4E2/CuCl2 treatment. Copper ions are known
to be associated with purine bases in the DNA, thus imparting site specificity for
oxidation of Guanine bases (Oikawa et al., 2001). However, we are currently
unable to speculate on the mechanism of induction of novel polar adducts as
they are as yet unidentified. Nevertheless, we have used the non-enzymatic cellfree system effectively, to screen agents that reduce total oxidative DNA damage
induced by 4E2/CuCl2. This, in turn, has further application in selecting agents
that may be effective in mammary cancer reduction since oxidative DNA damage
induced by estradiol metabolites is linked to mammary cancer incidence (Bolton
et al., 2000; Cavalieri et al., 2000; Anderson et al., 2003).
Ellagic acid, a polyphenol present in berries and a touted antimutagenic
agent, is very effective in reduction 8-oxodG, a known mutagenic lesion
(Srinivasan et al., 2002). In this study, ellagic acid showed a dose-dependant
modulation of many oxidative DNA adducts and reduced the levels of unidentified
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adducts even at 10 µM, whereas a much higher concentration of ellagic acid (100
µM) is required to inhibit 8-oxodG (Figure 2.4-Inset), suggesting that these 2
lesions may develop via separate mechanisms. Singlet oxygen is known to play
a predominant role in the generation of 8-oxodG, whereas the hydroxyl radical
causes a more promiscuous damage to all DNA bases (Hiraku et al., 2001;
Frelon et al., 2003). Thus, ellagic acid may be more effective in protecting
against hydroxyl radical induced DNA damage at lower concentrations. Further, it
is reported that ellagic acid covalently binds with DNA, but with a higher affinity to
poly (dAp X dTp) than poly (dGp X dCp) (Dixit & Gold, 1986; Teel, 1986). Such
selective interactions with the DNA bases may also explain the differential effects
at lower doses. All other flavanoids tested have shown antioxidant effects in
several studies, however it appears that the prooxidant effects of some agents
(silymarin, ascorbic acid, epigallocatechin gallate etc., ) is due to the presence of
metal ions such as Cu+ (Anderson et al., 1994; Toyokuni & Sagripanti, 1996;
Duthie & Dobson, 1999; Srinivasan et al., 2002; Furukawa et al., 2003; Yen et
al., 2003). Although it is possible to provide a mechanistic explanation for the
pro-oxidant effect of these agents, the selection of an agent to be employed in
the next tier depended on its efficacy in the first tier. Also, though in vitro tests
provide an easy and fast analytical system to assess the efficacy of
chemopreventive agents with respect to a particular mechanistic aspect of
cancer, no in vitro system can completely predict the effect in vivo. However, it is
impossible to test every agent in an in vivo study. Based on these criteria, only
ellagic acid was selected to be employed in a short-term in vivo study since it
was the most efficacious in reducing in vitro oxidative damage caused by a
catechol-estrogen metabolite.
Liver is a primary organ involved in the first-pass mechanism that is
affected by both harmful and protective components of the diet. It is also a highly
metabolic organ that is exposed to high levels of oxidative DNA damage resulting
from normal metabolism. The ability of any dietary component to reduce the
levels of this oxidative DNA damage at baseline would make it an ideal
preventive agent in the presence of additional oxidative stress. To determine if
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berries and ellagic acid would protect against oxidative stress, we tested their
efficacy in reducing oxidative DNA damage in the liver of CD1 mice fed diet
containing 5% (w/w) of different berries, or 400 ppm ellagic acid. The berries
investigated have both different ellagic acid and total anthocyanin content –
raspberries (1500 ppm ellagic acid; 10,000 ppm total anthocyanin), strawberries
(500 ppm ellagic acid; 2,000 ppm total anthocyanins) and blueberries (<100 ppm
ellagic acid; 38,000 ppm total anthocyanins) (Daniel et al., 1989; Wu et al.,
2006). The dose of ellagic acid was selected based on earlier work by Stoner
and colleagues who showed the 400 ppm of dietary ellagic acid, when fed to rats
for 23 days, showed significant reduction in hepatic P450 content (Ahn et al.,
1996).

Further,

the

same

dose

was

also

effective

in

reducing

N-

nitrosomethylbenzylamine (NMBA)-induced esophageal tumors (Mandal &
Stoner, 1990). Both red raspberries and ellagic acid elicited similar effects in
reducing the baseline oxidative DNA damage. Since raspberries have the highest
ellagic acid content among the berries tested and showed similar effects as pure
ellagic acid, we explored the possibility of a shared mechanism in reducing DNA
damage. Gene-expression analyses suggested that this effect may posssibly be
due to up-regulation of DNA repair genes (Figure 6). Also, both raspberries and
ellagic acid modulate several genes in a similar fashion suggesting that the
ellagic acid content of raspberries may play a role in their effectiveness.
However, the concentration of ellagic acid available in the diet through
raspberries is 5 fold lower (75 ppm Vs 400 ppm), which shows that ellagic acid
which is present as ellagitannins in berries, may be more bioavailable from
berries. Indeed 5% strawberries were more effective than 400 ppm ellagic acid
reducing NMBA-induced esophageal tumors (Mandal & Stoner, 1990; Carlton et
al., 2001). Further, raspberries contain moderately high levels of anthocyanins,
which are known antioxidants (Wang & Lin, 2000; Wu et al., 2006). This may also
account for their effectiveness. The results also show that P450s may be
differentially modulated with certain enzymes such as CYP 2A4 and 2E1 being
up-regulated and others such as 3A11 down-regulated. Several studies have
shown hepato-protective effects of ellagic acid such as protection against metaltoxicity and carbon-tetrachloride induced liver fibrosis (Thresiamma & Kuttan,
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1996; Ahmed et al., 1999; Singh et al., 1999). It is clear from our results that
ellagic acid and raspberries are hepato-protective via similar mechanisms and
are highly effective in reducing baseline oxidative DNA damage. Also, these
agents show up-regulation of DNA repair genes. Since breast cancer involves
both increase in DNA damage as well as decrease of DNA repair induced by
estradiol and its metabolites (Malins et al., 2006), ellagic acid and berries may
provide protection in estrogen-induced mammary cancer.
This study shows that ellagic acid is highly effective in preventing oxidative
DNA damage both in vitro and in vivo. Further, the prevention of oxidative
damage induced by 4E2, which is a postulated carcinogenic metabolite in breast
cancer, suggests that ellagic acid may be a good candidate for the prevention of
mammary tumorigenesis. In addition, raspberry a natural source of ellagic acid
has similar effects via similar mechanisms also making it a suitable candidate for
nutritional intervention.

This warrants the application of both ellagic acid as a

pure compound and in whole food (berries) in further long-term studies to test
their effectiveness against mammary carcinogenesis.
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Figure 2.1. Experimental protocol- effect of berries and ellagic acid on DNA
damage and gene expression in a short term in vivo study.
Five groups of 8 wk-old female CD-1 mice (n=6) were fed ad libitum, either a
control diet (AIN-93M) or diet supplemented with 5% (w/w) strawberries,
blueberries, raspberries or ellagic acid. Liver was analyzed for adduct levels
and gene expression as described in Materials and Methods.
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labeled and separated using two directional TLC. D1 (bottom to top) and D2 (left
to right) solvents as described in materials and methods.

54

Percentage of Vehicle control

350

*

300

*

250

*

200
150
100
50

*

El

Ve
h
la icle
gi
c
ac
Vi
i
ta d
m
i
N
ar n E
in
g
B e ni
io
n
ch
an
R
es
ve in
Fe rat
ru rol
lic
ac
Q
ue id
rc
et
Si
Ep
i
ly n
ig
A
sc ma
al
lo
rin
ca orb
i
te
c
ch
a
in c i d
ga
lla
te

0

Figure 2.3. Modulation of oxidative DNA adducts by various phytochemicals.
The modulation of unidentified polar oxidative adducts is shown as a percentage
of the vehicle control. The mean of 4 analytical replicates were compared by oneway ANOVA followed by Dunnett’s post hoc test. A P-value <0.05 was
considered significant and is denoted by an asterisk.
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Figure 2.4. Effect of different concentrations of ellagic acid on oxidative DNA
damage.
Both unidentified polar adducts ( ) and 8-xodG ( ) were measured using32Ppostlabeling/TLC and are represented as mean ± SE of 4 replicates. The inset
shows the effects at lower concentrations. The test for linear trend was
statistically significant with a p-value <0.0001.
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Figure 2.5. Comparison of diet consumption (A) and weight gain (B) between
CD-1 mice fed different diets in a shot-term in vivo study.
The diet consumption and weight gains were recorded over a period of 5 weeks
between CD-1 mice (n=6) fed control diet ( ) or diet supplemented with either
5% w/w berries (blueberry- ; strawberry-

; red raspberry -

) or 400 ppm

ellagic acid ( ). Diet was weighed everyday and the consumption was calculated
as described in Materials and Methods.
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labeled TLC maps of subgroups of adduct. Each subgroup of adducts was
visualized in the D1 using different salt concentration depending on their polarity
as described in Materials and Methods.
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Figure 2.7. Genes with significantly altered expression in the liver of mice fed
either 5% (w/w) raspberry- (A) or 400 ppm ellagic acid - supplemented diet (B).
TST-Thiosulphate sulphur transferase; XPA- Xeroderma Pigmentosum group A
complementing protein; ERCC5 - excision repair cross complementation group 5;
DNL3 - DNA Ligase III; SOD –Superoxide Dismutase, extracellular; MAPKMitogen activated protein kinase; MAPKK-MAP Kinase kinase. Gene expression
analyses were done in Dr. Margie Clapper’s laboratory at the Fox Chase Cancer
Center, Philadelphia, PA.
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Table 2.1. Comparison of modified diet composition to AIN-93M diet.

Ingredients

Percent of composition
AIN-93M diet

Modified diet

Corn starch

46.6%

36.03%

Dextrose

15.5%

36.04%

Sucrose

10%

0%

Total CHO calories

72.1%

72.07%

Casien

14%

14%

Soy Bean Oil

4%

4%

Fiber

5%

5%

AIN93 Vitamin Mix

1%

1%

AIN93 Mineral mix

3.5%

3.5%

L- Cysteine

0.18%

0.18%

Choline Bitartrate

0.25%

0.25%

A modified version of the AIN-93M diet was fed to the mice. Diet ingredients were
purchased individually from Dyets Inc., (Bethlehem, NJ) and mixed according to
the given composition in a Hobart mixer until homogenous. The corn starch
component was substituted for 5% berry diets such that the percentage of corn
starch in these diets was 31.03%. No substitutions were done for the ellagic acid
diet since this agent was added in insignificant quantities (0.04%). The diets were
stored either at -80°C (>1 week) or 4°C (<1 week) until use. CHO- Carbohydrate.
The composition of AIN-93M diet as described in Reeves et al., 1993.
Copyright © Harini Sankaran Aiyer, 2007
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Chapter Three: Effect of dietary berries and ellagic acid on estrogen–
induced mammary tumors in ACI rats.

Introduction
Breast cancer is the most commonly diagnosed cancer among women in the
United States. Among the women diagnosed, over 53,000 women are expected
to have ductal carcinoma in-situ (DCIS) (ACS, 2007a). DCIS remains one of the
most commonly diagnosed breast cancers, with up to 25% recurrence as
invasive carcinomas (Silverstein et al., 1995). Prolonged exposure to
physiological levels of 17ß-estradiol (E2) is considered as a key risk factor for the
development of sporadic breast cancer (Verheul et al., 2000; Lippman et al.,
2001). Furthermore, associations between the use of hormone-replacement
therapy and development of breast cancer in post-menopausal women (Verheul
et al., 2000; ACS, 2007b; ACS, 2007a) delineates a role for estrogens in human
breast cancer.
Typically, in animal models, mammary tumors have been induced using
carcinogenic doses of chemicals such as dimethylbenz[a]anthrazene, N-methylN-nitrosomethylurea, etc., (Cohen et al., 1999; Kim et al., 2004). Etiologically,
exposure to any carcinogen in humans is usually chronic with DNA damage
accumulating over a period of time, making exposure to bolus doses of
carcinogens less relevant to the human scenario. Thus, there is a need for a
relevant animal model to study breast cancer. August-Copenhagen Irish (ACI) rat
strain is highly susceptible to estrogen-induced mammary tumors (Shull et al.,
1997; Li et al., 2002b). These rats develop mammary tumors that bear close
resemblance to human breast tumors in both histopathological and molecular
aspects (Li et al., 2002a; Weroha et al., 2006). In addition, the etiology of disease
development is also similar to the human scenario, with tumorigenesis occurring
after chronic exposure to E2 (Shull et al., 1997; Li et al., 2002b). Thus, the ACI
rat model is highly relevant for chemopreventive intervention and translational
research.
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Translational research of cancer chemoprevention involves three major steps.
First, epidemiological studies find an association between certain foods/diet and
reduction in cancer incidence. Second, observational studies identify and employ
the most potent components in these foods in various in-vitro and in-vivo assays
to discover pathways, identify biomarkers and establish safety information. The
last step is to employ these agents in clinical trials, and use established
biomarkers to determine if the agent actually prevents or ameliorates cancer.
Unfortunately, some of the agents identified and employed using this 3-step
approach failed to show expected results in clinical trials (Hampton, 2005).
Potential reasons for this failure are as follows: since most chemoprevention
studies in animal models were performed using large doses of chemical
carcinogens, mega-doses of chemopreventive agents were required for efficacy
(Yuri et al., 2003). Thus, the pharmacologic dose derived from such studies may
result in adverse effects in humans. The concept of lower, more realistic doses of
chemopreventive agents has been proposed after the high-dose adverse
phenomenon observed in the CARET trials (Goodman et al., 2004). Also, most
observational studies fail to recognize the presence of and interactions between
the different components found in whole foods (Meyskens & Szabo, 2005). The
fractionation of a preventive food, green tea for example, usually yields one
major component (epigallocatechin gallate) that is most effective and several
other minor components that are somewhat less effective (Yang et al., 2000).
Nevertheless, the fact that there are several minor components that may play a
role in the protective effect of the food is not commonly acknowledged
(Meyskens & Szabo, 2005). These oversights may precipitate in the failure of an
agent to elicit any positive response or even adverse effects in humans
(Hampton, 2005).
Ellagic acid is a polyphenol formed by the dimerization of gallic acid in various
plants (Maas et al., 1991). It has been shown that ellagic acid may elicit cancer
prevention by several mechanisms which include direct binding to DNA,
attenuation of carcinogen metabolism via the P450 pathway, and downregulation of cell-cycle activators and up-regulation of pro-apoptotic mechanisms
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(Reviewed by Stoner & Mukhtar, 1995 and by Aggarwal & Shishodia, 2006).
However, the bioavailability of ellagic acid as a pure compound after oral
administration has been in question (Smart et al., 1986; Teel & Martin, 1988).
The effects of ellagic acid intervention on tumors other than those of the gastrointestinal tract have largely been unexplored due to its suspected low
bioavailability.
Ellagic acid in plants is present as ellagitannins (Larrosa et al., 2005). It is
released in the gut by the microflora and then absorbed as ellagic acid. Analysis
of ellagic acid contents of various berries shows that while some commonly
available berries such as black berries and raspberries are rich sources (1,500
ppm) others like blueberries (<100 ppm) are not (Daniel et al., 1989b). Several
studies by Stoner and colleagues have shown the protective effects of black
raspberries on gastro-intestinal tumors induced by chemical carcinogens (Harris
et al., 2001; Kresty et al., 2001; Stoner et al., 2006). Although black raspberries
and blueberries are good sources of anthocyanins, they differ significantly in their
anthocyanin profile (Wu et al., 2006). Black raspberry is a rich source of cyanidinpolymers whereas blueberry has a much wider range and is especially rich in
delphinidin-polymers (Wu et al., 2006). Blueberry has been much touted for its
antioxidant properties, both historically and experimentally due to its anthocyanin
content (Lau et al., 2005; Yi et al., 2005).
These facts formed the basis for the three-fold rationale of this study. First,
we examined the efficacy of relatively low doses of natural chemopreventive
agents, such as ellagic acid and berries, in reducing estrogen-mediated
mammary tumors in ACI rats, so that maximum clinical relevance can be
established from the results. Second, we provided both berries, a natural source
of ellagic acid and pure ellagic acid in the diet to distinguish the effects of “whole
food” versus “active ingredient” in its biological response. Finally, we chose
berries which differed widely in their ellagic acid contents but had similar total
anthocyanin levels to evaluate the role of each of the antioxidant components in
yielding benefits.
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In

this

chapter,

the

results

from

3

independent

studies

involving

supplementation with various berries and also involving 2 related animal models
of estrogen-induced mammary carcinogenesis are presented.
Materials and Methods
Diets. Diets for Study 1 were ordered from Bio-Serv (Frenchtown, NJ) and
diets for Studies 2 and 3 were ordered from Harlan-Teklad, Inc. (Madison, WI).
The AIN-93M diet was supplemented with powdered berries (2.5% w/w) or
ellagic acid (400 ppm). For Study 1, equal mixture of 5 different berries- red
raspberry, black raspberry, blackberry, blueberry and strawberry- were used
such that each berry constituted 0.5% (w/w) of the diet.
The black raspberries were procured as a freeze-dried powder from Van
Drunen farms, (Momence, IL), through Dr. Gary Stoner of The Ohio State
University (Columbus, OH). The processing of black raspberries was done as
described (Harris et al., 2001). All other berries were obtained as organic, fresh
produce and processed in the laboratory. Blueberries were purchased from a
local farm (Liberty, KY). Three different high bush cultivars of blueberry (V.
corymbosum L) - Bluecrop, Berkeley and Bluejay - were harvested in the
morning, stored overnight below 10ºC and transported the next morning to the
laboratory for processing. Blackberries were purchased from Reed Valley
orchards (Paris, KY). Red raspberries and strawberries were purchased from a
local food co-op (Lexington, KY). All berries except black raspberries were
processed similarly. Berries were rinsed with water and dehydrated using
commercial food dehydrators (at 40° - 60°C). The dried berries were finely
powdered using a kitchen blender (Sumeet Asia Kitchen Machine, Sumeet
Research and Holdings Ltd., Chennai, India), sieved and lyophilized to remove
residual moisture. All berries were then vacuum packed and stored at -20°C until
use. The three different cultivars of blueberries were mixed in equal ratios prior to
mixing in diet. Ellagic acid (>96% purity) was purchased from LKT labs (St. Paul,
MN). The cornstarch and fiber components of the AIN-93M diet were replaced for
the berry diets, based on the nutritional information available for each berry
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(http://www.nal.usda.gov/fnic/foodcomp, Table 3.4). A proximate analysis was
performed at Harlan-Teklad (Madison, WI) to ascertain that the diets were
isocaloric. This included the measurement of protein (Kjeldahl method; factor
NX6.38 for milk protien), fat (ether extraction), crude fiber, moisture (at 70°C) and
ash (at 600°C). The carbohydrate levels were arrived at by subtraction of protein
and fat values from the total calories. The daily feed intake by animals was
assessed by subtracting the unused diet from the initial amount provided per
cage divided by the number of rats in the cage.
Animal studies. Study 1 and Study 2: Female ACI rats were 7-8 weeks
old when purchased and 10-11 weeks old when implanted with 3 cm silastic
implants containing 27 mg 17ß-estradiol. Study 1 was conducted as a pilot study
with number of animals as specified (Tale 3.1) and Study 2 was designed with
enough number of animals in each group to achieve statistical significance
(Table 3.2).
Study 3: Female ACI rats were 5-6 weeks old when purchased and 8-9
weeks old when implanted with 1.2 cm silastic implants containing 9 mg 17ßestradiol (Table 3.3). This study was perfomed to avoid the mortality associated
with the larger implant used in Studies 1 and 2.
Animal treatment and assessment of tumor indices. Female ACI rats
were purchased from Harlan-Sprague-Dawley, Inc. (Indianapolis, IN), housed
under ambient conditions and had access to food and water ad libitum. Animals
were acclimated for 1 week on AIN-93M diet prior to randomizing them into
different groups (Tables 3.1 -3.3). After feeding experimental diets for 2 weeks,
animals then received one of the three E2 implants - a 3 cm silastic implant
containing 27 mg 17ß-estradiol

or a 1.2-cm implant containing 9 mg 17ß-

estradiol as described (Shull et al., 1997; Ravoori et al., 2007) or sham implants,
depending on study design (Table 3.1-3.3).

Briefly, silastic tubing (Allied

Biomedical Inc., Ventura, CA) was cut in respective lengths and sealed at one
end using a silicone adhesive (Factor II Inc., Lakeside, AZ). They were then filled
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with 17ß-estradiol and the other end was sealed. These were then
subcutaneously implanted in to rats under isofluorane anaesthesia (Ravoori et
al., 2007). Animals were weighed biweekly after estrogen implantation to track
weight changes and disease progression. Starting at 12 weeks after estrogen
implantation, animals were palpated weekly for tumor appearance. The
frequency of palpation was increased to twice a week, upon appearance of the
first tumor, to record tumor latency and incidence. The experiment was
terminated after 24 weeks of estrogen treatment for Studies 1 and 2, and after 32
weeks for Study 3. At termination, animals were euthanized by CO2 asphyxiation
and examined grossly for the presence of mammary tumors. Each tumor was
excised and measured in all 3 dimensions using calipers and the tumor volume
was calculated using the standard formula for the volume of a spheroid - 2/3π
r1*r2*r3, where r1, r2 and r3 represent the radii of the tumor. The tumor volume
per animal is the sum of the volumes of all individual tumors. Representative
tumors were analyzed for histopathology to confirm that they were mammary
adenocarcinomas. The fixing, sectioning and H and E staining of the tissues
were done at the Pathology Core Lab at the University of Louisviile (Louisville,
KY), and the stained sections were examined by two trained pathologists – Dr.
Srivani Ravoori and Dr. Sunati Sahoo to determine that they were mammary
adenocarcinomas.
Analysis of 17β-estradiol levels. Trunk blood was collected from animals
after euthanasia and the serum estradiol levels were measured by Roche E170
immunoassay

analyzer

using

electrochemiluminescent

detection.

These

analyses were done in the Pathology department at the University of Louisville
Hospital under the supervision of Dr. James Miller and were paid for from grant
support.
Statistical analysis. Experimental data were analyzed using the Statistical
Analysis Software, SAS version 8. The longitudinal analysis of the data on body
weights was carried out using the PROC MIXED procedure. A linear trend for
weight change was established at p-value <0.0005. The differences in weight
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gains or losses between different groups were assessed using the same
procedure and, for this analysis, a p-value < 0.0001 was considered significant
due to large number of weight comparisons at 13 biweekly time points. The
tumor volume and multiplicity were compared using the General Linear Models
(SAS procedure PROC GLM ) and the Poisson Regression Model (SAS
procedure PROC GENMOD) procedures, respectively, and a p-value <0.05 was
considered significant. The difference in the mortality index was assessed using
the non-parametric survival analysis techniques and the log-rank test. All
statistical analyses except the non-parametric survival analysis and the log-rank
test, were done by our collaborator Dr. Cidambi Srinivasan, Department of
Statistics, University of Kentucky (Lexington, KY).
Results
Serum estrogen levels. Serum 17β-estradiol was analyzed only for Study
2. The levels were measured at 6 weeks and 25 weeks. At 6 weeks, the mean
serum estrogen levels were significantly (p<0.0001) elevated (194 ± 20 pg/ml) in
the treated versus control group (35 ± 9 pg/ml). The levels further increased
somewhat after 24 weeks of treatment (236 ± 24 pg/ml) but the increase was
insignificant. No significant change was seen in age-matched controls (44 ± 7
pg/ml). There was no effect of dietary supplementation on serum estradiol levels
at both 6 and 25 weeks. The serum E2 analysis for Study 3 were not performed
but were assumed to be similar to values from a similar model established in our
laboratory (65 ± 5 pg/ml at 12 weeks and 200 ± 44 pg/ml at 32 weeks ) (Ravoori
et al., 2007).

Effect of estrogen treatment and experimental diets on body weight.
For all studies conducted, measurement of diet intake showed no significant
difference between various groups, suggesting that berry supplementation had
no effect on the diet intake. Furthermore, animals gained weight progressively
irrespective of the implants; however, estrogen-treated animals gained more
weight than their sham counterparts starting at 4 weeks after the treatment,
irrespective of the diet, indicating that this weight gain was a direct result of the
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estrogen treatment (Figures 3.1- 3.3). Sham-treated animals on control diet
continued to gain weight until the end of the experiment in all studies (Figures
3.1-3.3). In Study 2, sham-treated animals receiving experimental diets also
showed similar trends in weight gain, except that diet supplemented with black
raspberries showed higher weight gain, starting as early as 2 weeks after the
experimental diet, but the difference was significant only after 20 weeks of the
dietary regimen (p <0.05) (Figure 3.2A). However, both proximate analyses of the
diets as well measurements of diet intake did not show a difference in caloric
intake between the groups.

Effect of berry- and ellagic acid-supplemented diets on the diseaseassociated weight loss. In Study 2, at 22 and 24 weeks, the difference in
weight between estradiol- versus sham-treated animals on same diet was
significantly lower (p<0.0001) for all groups (compare figures 3.2 A and B). In
contrast, none of the sham-treated groups lost weight until the end of the study
suggesting that the weight loss was a disease-associated phenomenon in the
estradiol-treated animals. Comparison of estradiol-treated groups on various
diets revealed that animals fed control diet lost the most weight, followed by
animals fed blueberry-, black raspberry- and ellagic acid-supplemented diets
(Figure 3.2B). Ellagic acid-fed animals showed significant resistance to weight
loss even towards the end of the study, i.e., from the 20th (p< 0.05) to the 24th
week (p<0.005). Thus, there was an intervention-associated prevention of
weight-loss in all estradiol-treated animals, with ellagic acid-supplemented diet
showing the most-pronounced effect. Although similar trends were seen in Study
1, the effect did not achieve statistical significance due to small sample size.

Effect of estrogen treatment and experimental diets on the rate of
mortality. In Study 2, the morbidity in estradiol-treated groups was defined by
the loss of >7g a week. This was based on the weight gain comparison in shamtreated animals, whose weight gain was ≥ 3g per week. In addition, other
parameters such as loss of mobility, balance, grooming, the presence of eye
deposits and a dull hair coat were taken into account and scored subjectively on
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a scale of 1 to 5 (1 being the best and 5 being the worst). Animals that did worse
(score > 3) on 3 or more of these criteria and also had rapid weight loss were
euthanized. This was taken as indicator of the mortality (Figure 3.4). Additionally,
animals whose tumor size had reached >1.3 cm in diameter were also
euthanized. These animals, however, were excluded from the mortality index
because they did not meet the morbidity criteria. Estrogen-treated animals on
control diet showed the highest morbidity and mortality rate starting at 18 weeks
after the treatment. The survival rate in this group progressively declined,
reaching <50% after 24 weeks, thus only 11 of 25 animals survived at the
termination of the study. In contrast, all intervention groups were significantly
different from the control diet (log rank test, p-value <0.005): Both ellagic acidand blueberry-fed animals showed no morbidity and had >85% survival at 24
weeks. The group on black raspberry-supplemented diet initially showed a higher
survival rate, but it declined rapidly and had 60% mortality at 24 weeks. Although
the ellagic acid group showed no sign of morbidity, 3 out of 22 animals had to be
euthanized before 24 weeks because of the large tumors. These data suggest
that the disease progression, as measured by the incidence of morbidity, was
significantly delayed by the intervention - by about 3 to 6 weeks compared with
the control group.
In Study 3, there was no treatment associated mortality. This study
employed the improved model of estrogen-induced mammary carcinogenesis
first described by others in our laboratory (Ravoori et al., 2007, in press). This
model significantly eliminates disease associated mortality at the cost of a slightly
extended tumor latency period (32 versus 24 weeks). However, animals were
euthanized before the final termination if the tumor size reached >1.3 cm in
diameter. These animals are not included in the final comparison of tumor
indices. It is notable to mention that, the control diet showed the highest animal
loss before 32 weeks (5 out of 21) compared to diets supplemented with 2.5%
blueberry (2/16), 1% black raspberry (1/16), 2.5% black raspberry (0/16) and 400
ppm ellagic acid (3/16), suggesting the preventive effects of supplementation on
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tumor progression. The loss for animals supplemented with 1% blueberry was
not different from the control (4/17).
Effect of experimental diets on tumor indices. Tumor incidence was 100%
in all 17ß-estradiol-treated animals in all studies. The results for individual studies
are described below.
Study 1. Tumors were first noticed at 150 days after estrogen treatment;
however, this was not the first incidence as systematic palpation after 12 weeks
was not done for this study. Also, though there was no mortality in this study, the
tumor data for 4 animals from the ellagic acid group could not be obtained and
are not included in the calculations. There was no difference in tumor latency or
tumor incidence between the groups. On termination, the tumor multiplicity in the
control diet group was 9.0 ± 1.6 and tumor volume was 4,231 ± 1,675 mm3. Only
tumors that were larger that 0.5 cm were analyzed for histology. In this particular
study, a number of smaller tumors (1-2mm in diameter) were seen. Due to the
peculiarity of this animal model, where gross examination of mammary tumors
presents as a cluster of smaller tumors joining to form a bigger tumor, all nodules
that appeared in the mammary regardless of their size or appearance were
counted as mammary tumors. This may have lead to the over-estimation of the
number of tumors in all groups, especially since lymph nodes often look like
tumors on gross examination. Therefore, only tumor volume and to some extent
tumor burden are reliable measurements of tumor indices in this pilot study.
Blueberry diet reduced both tumor volume and volume/tumor by 70% (p< 0.001)
and 84% (P< 0.0001) respectively. Mixed berries reduced tumor volume by 75%
(p <0.01) and volume/tumor by 60% (p< 0.02). Although, ellagic acid reduced
tumor volume by > 40% and volume/tumor by >65%, it was statistically
insignificant (Table 3.5, Figure 3.7).
Study 2. The first palpable tumor was detected at 90 days after estradiol
treatment without any intervention, with a mean tumor latency of 134 ± 6 days.
The tumor development was marginally delayed in the intervention groups by 18,
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20 and 21 days for animals fed blueberry-, black raspberry- and ellagic acidsupplemented diets, respectively (Figure 3.5). However, there was no significant
difference in the mean tumor latency between the intervention groups and was
143 ± 5; 140 ± 6; 141 ± 6 for blueberry, black raspberry and ellagic acid
supplemented diets respectively. On termination after 24 weeks the tumor
multiplicity in the control diet group was 7.9 ± 2.4 and the tumor volume was 685
± 206 mm3 (Table 3.6). All tumors were confirmed to be mammary
adenocarcinomas through histopathology (Figure 3.9). Blueberry diet resulted in
a 40% reduction in tumor volume without any change in tumor multiplicity. Black
raspberry diet resulted in a 70% reduction (p<0.05) in tumor volume and nearly
40% reduction in tumor multiplicity. Ellagic acid showed the highest reduction in
tumor volume (>70%; p<0.05) and tumor multiplicity (>43%; p<0.05) (Table 3.6,
Figure 3.8).
Study 3. In this study, two different doses of each berry were tested- the
same dose (2.5% w/w) as used in Study 2 and a lower dose (1% w/w). The
results are summarized in Table 3.7 and presented in figure 3.10. The first
palpable tumor appeared 127 days after estrogen treatment in the control diet
group, with a mean tumor latency of 154 ± 4 days. There was no difference in the
appearance of the first palpable tumor between the groups (Figure 3.6).
However, the mean tumor latency for each group was: 1% blueberry-152 ± 6;
2.5% blueberry-162 ± 6; 1% black raspberry-168 ± 6; 2.5% black raspberry-149 ±
6; 400 ppm ellagic acid 170 ± 5. At termination of the study, the mean tumor
volume was 2804 ± 547 mm3 in the control diet group and tumor multiplicity was
11.7 ± 1.4. None of the tumor indices measured was reduced by the 1%
blueberry diet suggesting that blueberries may be ineffective at this dose (Table
3.7). At the 2.5% dose, blueberries reduced tumor volume by 45%, tumor
multiplicity by >30% (p < 0.05) and volume/tumor by 43%. Black raspberry at
both doses tested (1% and 2.5%) had similar effects on reducing tumor
multiplicity (30% reduction; p< 0.05), however they varied in their effects on
tumor volume, hence volume per tumor. The higher dose had a greater effect in
reducing tumor volume (56% versus 33%). Ellagic acid reduced tumor volume,
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multiplicity and volume per tumor by 45%, 37% (p< 0.05) and 47% respectively.
The reductions in tumor volume and volume per tumor were not statistically
significant due to high intra-group variability (Table 3.7).
Discussion
The application of preventive agents in randomized clinical trials involves
three distinct steps: First, epidemiological studies reveal a correlation between
the high intake of a particular food/diet and low prevalence of a certain disease.
Second, data from both in vitro and in vivo studies usually in rodent models
provide validation of these correlations. The initial step in this process is to
analyze and fractionate the different components of the whole food, and find
which of the component(s) are most effective. Although rodent studies are highly
dependent upon pharmacological response, the studies generally use high doses
of carcinogens, which in turn require high doses of chemopreventive agents to
elicit biological response (Yuri et al., 2003). The ACI rat model is highly
amenable to translational prevention research due to its steady exposure to
estrogen. However, only few intervention studies have been reported in ACI rats
where mammary tumors are induced by E2. Among these, Shull and co-workers
examined the effect of hypo-caloric feeding on reduction of mammary gland
tumors (Harvell et al., 2002) and Li and his team examined the chemopreventive
effect of tamoxifen (Li et al., 2002b) and both studies reported effective
inhibitions of mammary tumorigenesis. In our studies we have investigated the
efficacy of both the whole food (berries) and one of its principal components
(ellagic acid) in reducing estrogen-mammary carcinogenicity in the ACI rat
model.
The third and final step in translational research is employing effective
agents in clinical trials to ameliorate disease incidence in humans. The concept
of “pharmacological intervention” versus “dietary supplementation” must be
clearly differentiated. The translation of an epidemiological observation through
experimental design cannot be effective unless the synergism between the
different components in the food is acknowledged (Block, 1995; Meyskens and
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Szabo, 2005). In this study we have addressed these issues by adopting a
unified approach to chemoprevention.
Ellagic acid administered orally was initially shown to reduce tumors in both
mouse-skin and mouse-lung tumor models (Lesca, 1983; Mukhtar et al., 1984a;
Mukhtar et al., 1986).

The various mechanisms attributed to these effects

included direct binding of ellagic acid to the DNA and modulation of both phase I
and phase II enzymes involved in the metabolism of carcinogens (Reviewed by
Stoner and Mukhtar, 1995). Subsequent studies suggested that ellagic acid may
not be highly bioavailable, since >50% of the material administered orally was
excreted as such in feces and a large percentage of the material absorbed was
removed by the kidney (Smart et al., 1986; Teel & Martin, 1988). Thus, bioconcentration of ellagic acid may not be high enough to elicit a response in any
organ site peripheral to the gut, where it has been shown to persist for at least 24
h after gavage (Teel & Martin, 1988). Also, there is evidence that ellagic acid
strongly binds to all macromolecules in intestinal epithelial cells in tissue culture
(Whitley et al., 2003). The evidence taken collectively suggests that the gut may
be the prime organ where ellagic acid is effective in eliciting anti-tumor effects.
However, recently Stoner and colleagues have shown the presence of ellagic
acid in the plasma of human subjects fed black raspberries orally (Stoner et al.,
2005). Also, it is reported that about 0.2 to 2% of the orally administered dose
was found in peripheral organs after gavage (Smart et al., 1986; Teel & Martin,
1988), implicating that if provided via diet over time, steady-state levels could be
achieved.
Indeed, administered via diet at 400 ppm, ellagic acid was effective in
reducing 2-acetylaminiofluorene-induced hepatocellular carcinomas in ACI/N rats
(Tanaka et al., 1988). However, when given at 8,000 ppm 4 weeks prior to 7,12dimethylbenz[a]anthracene administration to Sprague-Dawley rats, ellagic acid
achieved only a modest (20%) reduction in mammary tumor incidence
(Singletary & Liao, 1989). Also, doses of 4,000 and 8,000 ppm ellagic acid failed
to elicit significant response in azoxymethane-induced colon tumors (Rao et al.,
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1991). Subsequently, Mandal and Stoner (Mandal & Stoner, 1990) demonstrated
interplay between carcinogen and ellagic acid dose ratios, in a rat-esophageal
tumor model. So far, ellagic acid has only been tested in animal models where
tumors are induced by bolus doses of carcinogens. As discussed earlier, ACI rat
model differs vastly from other chemical carcinogen-induced rodent tumor
models in that it delivers a steady dose of the carcinogen over the entire duration
of the tumorigenesis. Thus, the effects of bioavailability and bioconcentration in
meeting the carcinogen challenge are altered. Further, it has been shown that
both ellagic acid and several anthocyanins may act as a selective estrogen
receptor mediators, which may partially account for their effect in our study
(Schmitt & Stopper, 2001; Larrosa et al., 2006).
Berries vary in their contents of ellagic acid from < 100 ppm (blueberry) to >
1500 ppm (black raspberry) (Daniel et al., 1989a; Harris et al., 2001). In Study 1,
various berries were tested as a mixture to assess whether berries have some
efficacy against estrogen-induced mammary tumors or not. Nevertheless, both
the mixed berries as well as black raspberries provided a high-ellagic acid group
to contrast with the effects of a low-ellagic acid group (blueberries only). Berries,
apart from being good sources of ellagic acid are also rich sources of other
phytochemicals such as anthocyanins, flavonoids such as quercetin, kaempferol,
and vitamins and minerals (Harris et al., 2001; Wada & Ou, 2002). Interesting to
note is that each berry has a significantly different anthocyanin and total
phenolics profile (Wada & Ou, 2002; Wu & Prior, 2005; Wu et al., 2006). While,
black raspberries are high in total anthocyanins, their anthocyanin source is
primarily cyanidin-polymers, whereas blueberries are known to contain several
different types of anthocyanins, including high levels of delphinidin-polymers (Wu
& Prior, 2005; Wu et al., 2006). Evidence suggests that several of these
molecules may have partial estrogenic activities (Schmitt & Stopper, 2001;
Larrosa et al., 2006). It is not known yet how these will affect an estrogeninduced mammary carcinogenesis model. The possible interactions and
outcomes are discussed in chapter 5 in some detail.
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Ellagic acid is released from the ellagitannins by the action of the gut
microflora (Larrosa et al., 2005). It is not known whether a natural source of
ellagic acid would result in a higher bio-availability due to synergistic effects of
other natural components. The level of ellagic acid in the black raspberry diet or
mixed berry diet is about 30 – 45 ppm (based on a 2.5% dietary dose), but it is
highly effective in reducing tumor indices (Table 3.1-3.3). Pure ellagic acid, at
about 10 times this dose elicits the same response. Thus, either ellagic acid is
more bioavailable from ellagitannins in berries, or other components of berries
such as anthocyanins as well as other flavanoids, work synergistically to offer
better protection. There is support for the latter, since blueberry, a poor source of
ellagic acid but rich in anthocyanins also elicits a moderate reduction in the
estrogen mammary carcinogenicity as well a significant reduction in morbidity.
Disease progression can be understood as the decline in health of the
animals as indicated by weight loss and increased morbidity score. It was
theorized that the estradiol doses given to these animals may have been too high
and the subsequent toxicity induced by the estradiol levels may have a
confounding effect on the actual effectiveness of these diets. Li and co-workers
in their initial work reported that animals implanted with 3 mg cholesterol pellet
had a serum estradiol levels <145 pg/ml at 6 months. These animals did not
show high mortality albeit a marginal weight loss (Li et al., 2002b). In a recent
report using the cholesterol pellet model, other investigators (Mesia-Vela et al.,
2006) reported that animals suffered significant weight loss even at 20 weeks.
The serum estradiol levels in these animals were >300 pg/ml at 6 and 12 weeks.
This suggests that a high serum estradiol level plays a significant role in inducing
morbidity in the animals.

It is clear from our results that although dietary

interventions were highly effective in reducing weight loss and morbidity (Figure
3.4), the relatively low doses of dietary intervention may have been insufficient to
completely protect from adverse effects of high circulating estradiol levels. Also,
the varying effects of the two berries in preventing the morbidity may be related
to the differences in their anthocyanin content as well as their anthocyanin
profiles (Figure 3.4), (Wu et al., 2006).
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Using an improvised model our laboratory has found that reduced serum
levels of estradiol delivered by shorter estradiol silastic implants can produce
100% tumor incidence at the expense of somewhat longer duration (7-8 months)
(Ravoori et al., 2007).This model was used in Study 3 and it was hypothesized
that lower doses of the berries would be effective in reducing mammary tumor
indices due to the presence of lower levels of circulating E2 . However, the results
from Study 3 fail to support this hypothesis (Study 3 versus Study 2) (Tables 3.2,
3.3). Although speculations about the estrogenic activities of berry components
and their interactions with the cellular signaling pathways may partially explain
the results, more investigation is necessary to ascertain the exact mechanisms.
In conclusion, these studies consistently show significant reduction of
estrogen-mammary carcinogenicity by dietary berries and ellagic acid. They also
reveal the in-vivo efficacy of berries and ellagic acid in reducing tumorigenesis in
an organ site other than the gut.
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Figure 3.1. Comparison of weight gain in animals supplemented with dietary
berries and ellagic acid and treated with either sham-implants or implants
containing 27 mg E2 in a pilot study.
Animals were weighed every fortnight until termination of study. Sham treated
(closed symbol); estradiol treated (open symbols). Control diet
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between the groups were not statistically significant due to low number of
animals per group.
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Figure 3.2. Comparison of weight gain in animals supplemented with berries
and ellagic acid and treated with either sham-implants or implants containing 27
mg E2. Animals were weighed every fortnight until termination of study.
3.2A -SH treated (closed symbols); 3.2B - Estradiol treated (open symbols).
Control diet
Ellagic acid diet

,

; Blueberry diet
,

,

; Black raspberry diet

,

;

. Statistically significant weight differences are indicated.

* - Statistically different from animals fed control diet (p < 0.05).
‡ - Statistically different from animals fed control diet (p < 0.005).
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Figure 3.3. Comparison of weight gain in animals supplemented with dietary
berries and ellagic acid and treated with either sham-implants or implants
containing 9 mg E2.
Animals were weighed every fortnight until termination of study.
Sham treated (closed symbols); E2 treated (open symbols).
Control diet
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; Blueberry diet (1% w/w)

Black raspberry diet (1% w/w)
acid diet

; Blueberry diet (2.5% w/w)
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. The differences were not statistically significant between the

estradiol treated groups at any time point. All estradiol treated groups were
significantly different from the sham treated group starting at 8 weeks after
treatment until the end of the study
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Figure 3.4. Kaplan-Meier survival curves for ACI rats with estradiol implants fed
different diets and treated with silastic implants containing 27 mg E2.
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Figure 3.5. Effect of diets supplemented with dietary berries and ellagic acid on
tumor latency in ACI rats treated with silastic implants containing 27 mg E2.
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81

; Ellagic acid diet

.

Tumor Latency –Study 3

% Tumor Incidence

100
80
60
40
20

32

28

24

20

16

0

Weeks after E2 implant
Figure 3.6. Effect of diets supplemented with berries and ellagic acid on tumor
latency in ACI rats treated with silastic implants containing 9 mg E2.
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Figure 3.7. Effect of diets supplemented with dietary berries and ellagic acid on
tumor indices of ACI rat mammary tumors induced by 27 mg E2 (pilot study).
The tumor multiplicity was compared with the GLM procedure and tumor volume
was compared using the GENMOD procedure as described in methods. A pvalue ≤ 0.05 was considered significant and is denoted by an asterisk.
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Figure 3.8. Effect of diets supplemented with dietary berries and ellagic acid on
tumor indices of ACI rat mammary tumors induced by 27 mg E2.
The tumor multiplicity was compared with the GLM procedure and tumor volume
was compared using the GENMOD procedure as described in methods. A pvalue ≤ 0.05 was considered significant and is denoted by an asterisk.
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Figure 3.9. Representative H&E sections of sham-treated rat mammary glands
(A) and mammary gland tumors (B-E) from Estradiol-treated rats.
Rats were fed Control Diet (A and B); Blueberry Diet (C); Black Raspberry Diet
(D); or Ellagic Acid Diet (E) respectively. Shown at 400X magnification. The
mammary tissues were processed in the Pathology Core Lab (University of
Louisville, Louisville, KY) and confirmation of mammary adenocarcinomas by
histopathologic exam was done by Drs. Srivani Ravoori and Sunati Sahoo.
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Figure 3.10. Effect of diets supplemented with dietary berries and ellagic acid on
tumor indices of ACI rat mammary tumors induced by 9 mg E2.
The tumor multiplicity was compared with the GLM procedure and tumor volume
was compared using the GENMOD procedure as described in methods. A pvalue ≤ 0.05 was considered significant and is denoted by an asterisk.
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Table 3.1. Experimental protocol- Study 1 –A pilot study to
asses the efficacy of berries and ellagic acid to inhibit
mammary tumorigenesis in ACI rats induced by 27 mg E2.

Diet

17ßEstradiol
(27 mg)

Number
of
animals

+
+
+
+

2

Control Diet - AIN 93M
2.5% Blueberry
2.5% Mixed Berry
400 ppm Ellagic acid

8
8
7
4

Seven to eight week old animals were received and maintained initially on AIN93M control diet for a week, followed by experimental diets for another 2 weeks
before 17ß-estradiol implantation. Animals were maintained on experimental
diets until the end of the study.
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Table 3.2. Experimental protocol- Study 2 –A study to
asses the efficacy of berries and ellagic acid to inhibit
mammary tumorigenesis in ACI rats induced by 27 mg E2.

Diet

Control Diet - AIN 93M
2.5% Blueberry
2.5% Black Raspberry
400 ppm Ellagic acid

17ßEstradiol
(27 mg)

Number
of
animals

+
+
+
+

6
25
6
20
6
19
6
22

Seven to eight week old animals were received and maintained initially on AIN93M control diet for a week, followed by experimental diets for another 2 weeks
before 17ß-estradiol implantation. Animals were maintained on experimental
diets until the end of the study.
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Table 3.3. Experimental protocol- Study 3 –A study to asses
the efficacy of berries and ellagic acid to inhibit mammary
tumorigenesis in ACI rats induced by 9 mg E2.

Diet

17ßEstradiol
(9 mg)

Number
of
animals

+
+
+
+
+
+

6

Control Diet - AIN 93M
1% Blueberry
2.5% Blueberry
1% Black Raspberry
2.5% Black Raspberry
400 ppm Ellagic acid

15
12
14
15
12
12

Five to six week old animals were received and maintained initially on AIN-93M
control diet for a week, followed by experimental diets for another 2 weeks before
17ß-estradiol implantation. Animals were maintained on experimental diets until
the end of the study.
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Table 3.4. Composition of AIN-93M diet and diets supplemented with various
levels of berries or ellagic acid.
Type of Diet
AIN-93M

1% BB

2.5% BB

1% BRB

2.5% BRB

EA

140.0

140.0

140.0

140.0

140.0

140.0

1.8

1.8

1.8

1.8

1.8

1.8

Corn Starch

465.3

458.4

447.4

462.5

457.7

465.3

Maltodextrin

155.0

155.0

155.0

155.0

155.0

155.0

Sucrose

100.0

100.0

100.0

100.0

100.0

100.0

Ingredient
Casein
L-Cystine

Soybean Oil

40.0

40.0

40.0

40.0

40.0

40.0

Cellulose (fiber)

50.0

47.3

43.3

43.2

33.0

50.0

AIN-93M Mineral Mix

35.0

35.0

35.0

35.0

35.0

35.0

AIN-93M Vitamin Mix

10.0

10.0

10.0

10.0

10.0

10.0

Choline Bitartrate

2.5

2.5

2.5

2.5

2.5

2.5

Blueberry powder

-

10.0

25.0

Black raspberry Powder

-

10.0

25.0

Ellagic acid

-

0.4

Starch equivalent from berries

-

6.9

9.6

2.8

7.6

-

Fiber equivalent from berries

-

2.7

6.7

6.8

17.0

-

Total starch

465.3

465.3

465.3

465.3

465.3

465.3

Total cellulose

50.0

50.0

50.0

50.0

50.0

50.0

The diets were ordered from Harlan-Teklad (Madison, WI). The cornstarch and
fiber components of the AIN-93M diet were replaced for the berry diets, based on
the

nutritional

information

available

for

each

berry

(http://www.nal.usda.gov/fnic/foodcomp). A proximate analysis was performed at
Harlan-Teklad (Madison, WI) to ascertain that the diets were isocaloric. BBBlueberry;

BRB-

Black

raspberry;
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EA-

Ellagic

acid.

Table 3.5. Study 1- Comparison of organ weights and tumor indices between
ACI rats fed control diet or diet supplemented with blueberries, mixed berries or
ellagic acid

Animal
Weight
(g)

Liver
(g)

Mammary
(g)

Tumor
Volume
(mm3)

Tumor
Multiplicity

Volume/
tumor
(mm3)

Control diet
(Sham) (n=2)

197 ± 11.5

6.1 ± 0.5

2.9 ± 0.8

NA

NA

NA

Control diet
(n=8)

195 ± 2.4

5.9 ± 0.3

3.8 ± 0.3

4231 ± 1675

9 ± 1.6

505 ± 238

194 ± 2.5

6.2 ± 0.2

4.8 ± 0.2

1278 ± 570
p < 0.001

12.7 ± 1.3
p < 0.05

81 ± 18.5
p<
0.0001

189 ± 3.3

5.8 ± 0.3

4.1 ± 0.4

1011 ± 262
p < 0.01

6 ± 1.0
p < 0.2

199 ± 78
p < 0.02

188 ± 3.1

6.3 ± 0.4

4.1 ± 0.7

2686 ± 1644
p < 0.5

13.5 ± 3.3
p < 0.08

167 ± 66
p < 0.05

Group

Blueberry diet
(n =8)
Mixed berry diet
(n=7)

Ellagic acid diet
(n= 4)

Animals were euthanized after 24 weeks of estrogen treatment. Organ wet
weights were measured after excision. Tumor volume was calculated as the
volume of a spheroid (2/3 π r1*r2*r3). Values denote mean ± SEM. “n”
designates only those animals that survived 24 weeks. All comparisons are
between 17ß-estradiol treated animals on control diet and respective diets.
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Table 3.6. Study 2- Comparison of organ weights and tumor indices between
ACI rats fed control diet or diet supplemented with blueberries, black raspberries
or ellagic acid

Animal
Weight
(g)

Liver
(g)

Mammary
(g)

Pituitary
(g)

Control diet
(Sham) (n=6)

189 ± 6

5.2 ± 0.2

3.7 ± 0.2

Control diet
(n=11)

169 ± 6.4

5.0 ± 0.3

Blueberry diet
(n =16)

159 ± 5.6

Black raspberry
diet
(n=11)

Group

Ellagic acid diet
(n=19)

Tumor
Volume
(mm3)

Tumor
Multiplicity

Volume/
tumor
(mm3)

Not
measured

NA

NA

NA

3.84 ± 0.3

0.22 ± 0.03

685 ± 240

7.9 ± 1.3

115 ± 39

4.7 ± 0.2

3.89 ± 0.3

0.19 ± 0.01

409 ± 73
p < 0.835

8.2 ± 1.0
p< 0.749

45 ± 7
p< 0.170

162 ± 8.5

4.7 ± 0.3

4.41 ± 0.6

0.25 ± 0.02

211 ± 69
p< 0.003

4.7 ± 0.7
p< 0.070

38 ± 10
p< 0.034

167 ± 4.3

4.9 ± 0.2

4.53 ± 0.3

0.19 ± 0.01

168 ± 34
p< 0.001

4.5 ± 0.5
p< 0.027

34 ± 7
p< 0.009

Animals were euthanized after 24 weeks of estrogen treatment. Organ wet
weights were measured after excision. Tumor volume was calculated as the
volume of a spheroid (2/3 π r1*r2*r3). Values denote mean ± SEM. “n”
designates only those animals that survived 24 weeks. All comparisons are
between 17ß-estradiol treated animals on control diet and respective diets.
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Table 3.7. Study 3 -Comparison of organ weights and tumor indices between
ACI rats fed control diet or diet supplemented with different doses of blueberries,
black raspberries or ellagic acid
Animal
Weight
(g)

Liver
(g)

Mammary
(g)

Pituitary
(mg)

Tumor
Volume
(mm3)

Tumor
Multiplicity

Volume/
tumor
(mm3)

Control diet
(sham) (n=6)

182 ± 4

4.6 ± 0.2

3.4 ± 0.2

9.6 ± 0.8

NA

NA

NA

Control diet
(n=17)

204 ± 2

6.8 ± 0.2

4.8 ± 0.3

69 ± 4.5

2804 ± 547

11.7 ± 1.4

308 ± 83

1 % Blueberry
diet
(n=12)

207 ± 3

6.9 ± 0.2

5.4 ± 0.2

58 ± 7

2280 ± 739

11.2 ± 1.9

208 ± 45

2.5% Blueberry
diet
(n=14)

203 ± 6

6.6 ± 0.3

5.7 ± 0.4

68 ± 15

1525 ± 457

7.3 ± 0.9
p< 0.05

176 ± 43

1 % Black
raspberry diet
(n=15)

201 ± 4

6.5 ± 0.2

6.2 ± 0.4

59 ± 10

1871 ± 479

6.9 ± 0.8
p< 0.008

233 ± 46

2.5% Black
raspberry diet
(n=16)

209 ± 6

6.7 ± 0.3

6.8 ± 0.6

43 ± 5

1241 ± 444

6.9 ± 1.3
p< 0.007

182 ± 45

208 ± 5

6.5 ± 0.2

5.5 ± 0.3

56 ± 5

1547 ± 639

7.2 ± 1.2
p< 0.05

163 ± 56

Group

Ellagic acid diet
(n=13)

Animals were euthanized after 32 weeks of estrogen treatment. Organ wet
weights were measured after excision. Tumor volume was calculated as the
volume of a spheroid (2/3 π r1*r2*r3). Values denote mean ± SEM. “n”
designates only those animals that were euthanized after 32 weeks. There was
no mortality; however animals were euthanized before 32 weeks if their tumors
were larger than 1.3 cm in diameter. All comparisons are between 17ß-estradiol
treated animals on control diet and respective diets.
Copyright © Harini Sankaran Aiyer, 2007
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Chapter Four: Effect of berries and ellagic acid on estrogen metabolism
during 17ß-estradiol- induced mammary tumorigenesis in the ACI rat.

Introduction
Estrogen is a known, yet unavoidable risk factor for breast cancer.
Women, exposed to even physiological levels of this hormone chronically are at
an increased risk to develop breast cancer (Lippman et al., 2001). This risk is
compounded by the presence or absence of several other factors. Although
certain women are genetically predisposed to breast cancer due to heredity, they
represent only a small fraction of women at risk (Brinton et al., 2002; Thompson
& Easton, 2004). On the other hand, a majority of the population is at a higher
risk due to polymorphisms in low penetrance genes, especially those involved in
estrogen metabolism (Nathanson & Weber, 2001). Estrogen metabolism occurs
in several tissues of the human body to varying extents and to achieve different
ends (Rieder et al., 1998; Simpson, 2003). The primary organ involved in
estrogen production is the ovary, under the control of anterior pituitary. However,
the important role of estrogen in the maintenance of homeostasis can be
garnered from the fact that several tissues are endowed with enzymes that can
both produce and conjugate estradiol (Simpson et al., 1994; Murray et al., 2001).
The breast, like several other tissues, is capable of producing estradiol via denovo pathways and these pathways coupled with estrogen metabolism and
signaling may play a major role in breast cancer. A simplified scheme for such
interactions is shown in figure 4.1.

Primary enzymes involved in de-novo

estradiol synthesis are aromatase, which converts androgen precursors to
estrone, and 17ß-hydroxysteroid dehydrogenase (17ßHSD), which converts
estrone (E1) to estradiol (E2) (Milczarek & Klimek, 2005; Sasano et al., 2006).
Another, minor pathway is via estrogen sulphatase that converts sulfated
estradiol/estrone to the original molecule (Sasano et al., 2006). Research
suggests that this in-situ sythesis of estradiol may play a major role in the
development of breast cancer, especially in post-menopausal women (Chen,
1998; Simpson, 2003).
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Aromatase is a target of current pharmacological therapy and the use of
aromatase-inhibitors has been successful in the treatment of estrogen-receptor
(ER) negative breast cancer (Tuxen et al., 2007). Another enzyme, also crucially
involved in E2 biosynthesis is 17ßHSD. Eight isozymes, present in several
tissues, have been identified so far and have both human and rodent
homologues (Luu-The, 2001). The type 1 isozyme of 17ßHSD, which converts
estrone to estradiol, is found in both normal and malignant breast (Miettinen et
al., 1996). The rodent homologue of this enzyme is 17ßHSD, type 7 (17HSD7),
also known as the prolactin receptor associated protein (PRAP) (Duan et al.,
1996; Peltoketo et al., 1999). This enzyme has high specificity for the conversion
of E1 to E2 and is controlled by both prolactin and estrogen signaling pathways
(Duan et al., 1997).
There are several phase I and phase II enzymes involved in the
metabolism of E2, of particular importance in the breast are Cytochrome P450
1A1 (CYP1A1), CYP1B1,

catechol-O-methyl transeferase (COMT), UDP-

glucuronosyl transferase (UGT) and Glutathione-S-transferase (GST). The phase
I enzyme, CYP1B1 has received wide attention due to its function in converting
E2 to 4-hyrdroxy estradiol (4E2), a postulated potentially carcinogenic metabolite
that causes oxidative DNA damage and induces renal-cell carcinomas in
hamsters (Liehr, 2000; Hiraku et al., 2001; Liehr, 2001). Also, breast tumors
show high levels of both CYP1B1 and 4E2 (McFadyen et al., 1999; Oyama et al.,
2005). Nevertheless, metabolites of CYP1A1 action such as 2-hydroxy estrone
can produce stable DNA adducts and inhibition of CYP1A1 metabolism reduces
the formation of estrogen-induced kidney tumors in hamsters, suggesting that
this pathway may also play a definitive role in estrogen carcinogenesis (Liehr et
al., 1991). The hydroxy-metabolites of estradiol and estrone are conjugated for
removal by several enzymes, including COMT, GST and UGT (Lakhani et al.,
2003; Abel et al., 2004). The 2-hydroxy metabolites are better substrates for
COMT (Liehr, 2000), suggesting that CYP1A1 and COMT expression may be
coupled. Polymorphisms in both phase I and II genes have been associated with
a risk of breast cancer, indicating the importance of these enzymes in the
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production and removal of estradiol metabolites (Gallicchio et al., 2006). The
estrogen metabolism pathway interacts with the estrogen-signaling pathway.
Hydroxy-metabolites of estradiol such as 4E2 and 2E2 bind to ERs with varying
affinities (Zhu & Conney, 1998). Thus, enzymes such as CYP1A1 and CYP1B1
are regulated by ERs (Tsuchiya et al., 2005; Sissung et al., 2006). Progesterone
receptor (PGR) is known to be up-regulated by estrogen via ER signaling, hence
PGR expression is a downstream effect of ER activation (Mauvais-Jarvis et al.,
1986b). Thus, studying the expression of these genes provides some idea about
control of estrogen metabolism in the mammary tissue.
Several epidemiological studies have shown that the high intake of fruits
and vegetables may reduce the risk of breast cancer (Block et al., 1992). Other
than being rich sources of vitamins and minerals, fruits are also sources of
phytochemicals (Forman et al., 2004). Several phytochemicals share a similar
chemical structure with endogenous steroids, thereby making them substrates for
steroid receptors and as well as steroid metabolizing enzymes (Dixon et al.,
2005). Indeed, berry phytochemicals such as anthocyanins and ellagic acid show
selective estrogen receptor modulating (SERM) activity in some studies (Schmitt
& Stopper, 2001; Larrosa et al., 2006). These phytochemicals are highly
bioavailable in both humans and rodents and hence may play a significant role in
modulating estrogen metabolism (Talavera et al., 2004; Tian et al., 2006). Data
presented in the previous chapter show that both berries and ellagic acid can
reduce estrogen-induced mammary tumorigenesis when provided via the diet.
However, the exact mechanisms by which they provide protection are not known.
In order to determine this we examined the regulation of expression of key
enzymes involved in estrogen metabolism and signaling, in the mammary tissue
of ACI rats treated with E2 by silastic implant during the course of mammary
tumorigenesis. The effect of dietary berries and ellagic acid on these enzymes
was also tested. Three time points – early (6 weeks), intermediate (18 weeks)
and late (24 weeks) were chosen and the expression of 9 selective genes, 3
each involved in the phase I , phase II metabolism and estrogen signaling (Figure
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4.1) were selected and their relative gene expression changes analyzed using
quantitative real time PCR. The genes tested were: phase I metabolism17ßHSD7, CYP1A1, CYP1B1; phase II- COMT, GSTA1, GSTM1; steroid
signaling – ERα, ERß, PGR. The results are presented herein.
Materials and methods
Animals, diet and treatment. Female ACI rats (7-8 weeks old) were
purchased from Harlan-Sprague Dawley (Indianapolis, IN), housed under
ambient conditions and fed AIN-93M diet and water ad libitum. After a week of
acclimation, 18 animals each were randomized into different groups as per table
4.1. Two of the 5 groups received control diet and the other 3 received diets
supplemented with 2.5% (w/w) blueberry; black raspberry or 400 ppm ellagic
acid. After 2 weeks of pre-feeding, each group received either sham implants or
E2 implants as described (Shull et al., 1997, Table 4.1). The animals were
maintained on their respective diets throughout the study period and 6 animals
from each group were euthanized at 6, 18 and 24 weeks after E2 treatment by
carbon dioxide asphyxiation, and mammary tissue was collected and frozen for
further analysis. Trunk blood was collected for measurement of serum estrogen
levels and for future analysis of serum phytonutrient levels.
RNA isolation. RNA from whole mammary tissue was isolated using the
Trizol® method (Invitrogen, Carlsbad, CA), with modifications. All procedures
were done in a RNase free environment.

Briefly, approximately 100 mg of

mammary tissue was suspended in 2 ml of Trizol® at 4°C and homogenized with
a hand-held polytron at maximum speed. This homogenate was then passed
through a syringe with a 22.5 gauge needle (Beckton-Dickinson and Co., Franklin
Lakes, NJ) to ensure complete dissociation of the mammary tissue. The 2 ml
homogenate was then divided into 2 aliquots of 1 ml each, distributed into 1.5 ml
tubes. After the addition of 200 µl chloroform the solution was vortexed briefly
and centrifuged at 13,000Xg for 15 min at 4°C. The resultant aqueous
supernatant was sequentially extracted with another 400 µl of chloroform and the
aqueous phase was precipitated using ice-cold iso-propanol. The RNA pellet was
97

recovered by centrifuging at 13,000Xg for 15 min at 4°C, washed with 70%
ethanol, dissolved in nuclease-free water and the aliquots were combined. The
quality of the RNA was ascertained by gel electrophoresis and quantitated using
NanoDrop® (NanoDrop Technologies, Wilmington, DE). The RNA was then
diluted to 5 ng/µl concentration and stored at -80°C until use.

Design and standardization of concentration for PCR primers.
Primers for quantitative real-time PCR were designed across exon boundary to
avoid amplification of genomic DNA, using Primer express® 3.0 software
(Applied Biosystems, Foster City, CA) and synthesized by Integrated DNA
Technologies, Inc., (Coralville, IA). The sequences of the forward and reverse
primers for each gene tested are listed in Table 4.2. The primers were tested at a
concentration of 500 nM each initially to ascertain the presence of primer-dimers.
If this was present, a dilution array containing varying concentrations of both
forward and reverse primers was done and the combination at which there was
uniform amplification and no byproduct was used further. For most genes tested
500 nM final concentration of each primer produced no primer-dimers, except for
CYP1A1 for which 125 nM each produced a single uniform peak. Both sense
and antisense primers were diluted such that 0.5 µl of the stock (10 µM or 2.5 µM
for 1A1) provided 500 nM (or 125 nM for CYP1A1) of each primer at a final
volume of 20 µl.
Real-time PCR efficiency studies. In order to ensure that all genes
reverse-transcribed with the same efficiency, reverse-transcription efficiency
studies were done initially. RNA of 3 animals from each group was pooled to
generate the single test sample for each group, and cDNA was synthesized
using the High capacity cDNA archive kit (Applied Biosystems, CA) in 10-fold
serial dilutions such that the RNA concentrations were –1 µg/µl, 100 ng/µl, 10
ng/µl, 1 ng/µl, 100 pg/µl, 10 pg/µl and 1 pg/µl. The conditions for the reverse
transcription were: 25°C for 10 min; 37°C for 2 hour; and 85°C for 5 seconds.
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The PCR amplification was done in a final reaction volume of 20 µl
containing 10 µl of 2X Power SYBR® Green PCR master mix (Applied
Biosystems, CA); 0.5 µl each of forward and reverse primers specific for each
gene (final concentration- 500 or 125 nM as mentioned) and 3µl of cDNA such
that the equivalent RNA concentration was- 3µg, 300 ng, 30 ng, 3 ng, 300 pg, 30
pg and 3 pg. Quantitative PCR was performed using a 7500 Fast-Real Time PCR
system (Applied biosystems, Foster City, CA) using the absolute quantification
protocol and standard curves generated. The PCR conditions were: 50°C for 2
min; DNA polymerase activation at 95°C for 10 min; followed by 40 cycles at
95°C for 15 seconds and 60°C for 1 min. The concentration range with a slope
closest to -3.3 was selected and the highest concentration in this range was used
for all further experiments. For all samples and genes tested, this concentration
was found to be 1 ng/µl for reverse transcription and 3ng for the PCR reaction.
Individual samples were analyzed henceforth using these standardized
conditions.

Analysis of gene expression.

Gene expression analysis was done

using the relative-quantification (∆∆cT) method as described (Livak and
Schmittgen, 2001). Each sample (refers to cDNA from individual animals) was
analyzed in triplicate for each gene tested and the average of these values was
taken as the cT value for that gene.

∆cT was calculated as the difference

between cT of gene of interest and the house-keeping gene (ß-actin) (∆cT =
cTGOI – cTß-actin). One sample (sham treated) was chosen as the calibrator and
∆∆cT of all other samples was calculated using the formula ∆∆cT = ∆cTsample ∆cTcalibrator. The fold change (2-∆∆cT) in gene expression was calculated for all
genes and samples. At each time point, for all genes tested, the calibrator
sample was the same (typically a sample from the sham treated group), such
that the results are represented as relative fold change, which represents the
biological variation within a specific group and absolute fold change, which is the
relative fold change of E2-treated groups divided by the relative fold change of
sham-treated group on control diet. The absolute fold change represents the
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actual up- or down-regulation of genes by the E2 treatment both in the presence
and absence of intervention, and is always 1 for the sham treatment.
Statistical analysis. Relative fold changes in each group were compared
using one-way analysis of variance (ANOVA), followed by a Tukey’s multiple
comparison post test. A p-value <0.05 was considered significant. All statistical
analyses were performed using the Graphpad Prism ® software (Graphpad
Software, San Diego, CA).
Results
Reverse-transcription efficiency studies. The reverse-transcription (RT)
efficiency studies were performed in order to confirm that all transcripts reversetranscribed at the same efficiency. The cDNA for each of the test samples was
made in 10-fold serial dilutions of individual RNA and each dilution was used in
PCR as described in materials and methods. In quantitative real-time PCR, every
cycle involves the doubling of the number of transcripts and hence a cyclethreshold (cT) value of 3.3 approximately indicates a 10-fold difference. Since,
the reaction kinetics can differ based on a number of factors including efficiency
of the enzyme, total number of transcripts, etc, it is important to assess the RNA
concentration at which all transcripts tested, amplify with the same efficiency. In
testing a series of 10-fold serial dilutions, a negative slope close to 3.3 would
indicate equivalent amplification. For most house-keeping genes tested this
range was 100 ng/µl to 1 pg/µl for the E2-treated group, however for the shamtreated group this range was 1 ng/µl to 1 pg/µl. For other genes tested, there was
no amplification in the lower pg/µl range. Thus, 1 ng/µl of RNA was reversetranscribed and 3ng cDNA equivalent was used for PCR amplification. The
validity of this concentration was further confirmed when a standard curve with a
negative slope of 3.3 was observed when using 10-fold serial dilutions of cDNA
prepared using 1 ng/µl RNA .

Changes in phase I enzymes at various time-points after estrogen
treatment. At 6 weeks after estrogen treatment, all phase I enzymes tested were
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significantly affected in the E2-treated groups compared with sham-treatment.
The levels of 17ßHSD7 was elevated by 4.8 fold (p<0.001) in E2-treated animals
maintained on control diet (E2-CD). However, this overexpression was partially
offset, i.e., only 1.8, 2.2 and 2.5 fold in blueberry, black raspberry and ellagic
acid groups respectively (Figure 4.2; Table 4.3). This anti-estrogenic effect was
not present at 18 and 24, weeks (Figure 4.5 and 4.8). The enzyme that showed
the highest up-regulation at 6 weeks was CYP1A1 with a 48 fold increase after
estrogen treatment (p<0.0001) and stayed elevated by 15 and 8 fold at 18 and 24
weeks respectively (p<0.001) (Figure 4.11; Tables 4.3 and 4.5). Both blueberry
and black raspberry diets significantly offset this elevation to 21 (p<0.01) and 12
(p<0.001) fold, respectively after 6 weeks of E2 treatment. This protection
continued at 18 weeks for blueberry diet but not for black raspberry (Figure 4.5).
Ellagic acid diet showed effects similar to control diet at all time points. At 24
weeks, the elevations in CYP1A1 were only slightly offset, with black raspberry
showing the greatest reduction (p<0.05) (Figure 4.8; Table 4.5). CYP1B1 was
significantly down regulated by estrogen treatment at all time points tested
(p<0.001) (Figures 4.11). All diets at 6 weeks, suppressed CYP1B1 expression
by up to 5 fold compared with E2-treated animals on control diet and by up to 11
fold compared to sham-treated animals (Figure 4.2; Table 4.3). These changes
were not seen at other time points.

Changes in phase II enzymes at various time-points after estrogen
treatment. In general, COMT and GSTA1 were up-regulated by estrogen
treatment. At all time points, COMT increased by up to 2 fold (p<0.05) after
estrogen treatment for the control diet and this was attenuated by dietary
intervention significantly only at 18 weeks (Figure 4.6; Table 4.4). At 6 and 18
weeks, GSTA1 was up-regulated by estrogen treatment and dietary intervention
did not have any significant effect on this increase. At all time points, GSTM1
was, however, found to be down-regulated after estrogen treatment by up to 3
fold (p<0.05) with no effect of intervention.
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Changes in steroid receptors various time-points after estrogen
treatment.

The estrogen receptor α (ERα) was significantly down-regulated

(p<0.001) by estrogen treatment throughout the study period (Figure 4.13; Tables
4.3 to 4.5). Neither berries nor ellagic acid affected this change (Figure 4.13). On
the other hand, ERß was unaffected by estrogen treatment (Figure 4.13).
Progesterone receptor was significantly up-regulated at both 6 and 18 weeks
after estrogen treatment (Figure 4.8, 4.9 and 4.13).
General trends in gene-expression modulation. In general, it was seen
that estrogen treatment had a uniform effect on the regulation of several
estrogen-metabolism genes tested and the greatest difference in most genes
was seen at the earliest time point- 6 weeks after treatment (Figure 4.11 to 4.13).
At 18 weeks, there were fewer genes that were differentially modulated and the
effect was lower. At 24 weeks for most genes tested, all E2 treated groups,
regardless of supplementation, appeared to have similar levels of expression.
On one hand, CYP1A1 is highly over-expressed beginning at 6 weeks
after treatment and the expression changes are maintained to a lesser extent at
both 18 and 24 weeks. This up-regulation is countered effectively by both the
berry diets, especially at 6 weeks, but not by ellagic acid. On the other hand,
CYP1B1 expression is down-regulated after estrogen treatment. The trend of
down-regulation is the highest at 6 weeks and subsequently reaching a plateau
at 18 and 24 weeks (Figure 4.11). There is a similar response for 17ßHSD7,
which suggests that the early gene regulation after estrogen treatment can be
seen at 6 weeks, when the E2 levels are increasing and that this expression
changes reach a plateau, possibly due to acclimatization of the tissues to high
circulating E2. The effects of supplementation can also be seen at this early
stage, with most of the differences between control diet and supplemented diet
seen at 6 weeks. The only exception to this was COMT, for which the difference
in modulation was seen at 18 weeks. The genes for which there are no
considerable differences between groups are ERß and GSTM1, with the latter
being down-regulated after estrogen treatment with no change between control
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and supplemented diet. Although GSTA1 is over-expressed after estrogen
treatment at 6 weeks, the change is statistically insignificant (Figure 4.5), but is
significant at 18 weeks. PGR is over-expressed at 6 and to lesser extent, at 18
weeks, but not at 24 weeks. However, there was no effect of the supplemented
diets on these changes. These trends signify that these agents may act
differentially through multiple signaling pathways.
Discussion
The results presented show the modulation of selected genes involved in
phase I, phase II estrogen metabolism, and receptor signaling at different time
points after E2 treatment, and the effect of diets supplemented with blueberry,
black raspberry, and ellagic acid. Since several variables are involved, the effect
of estrogen treatment per se on the different genes, the modulation of these at
different time points, the effect of supplemented diets on estrogen-induced
modulation at specific times, and the possible reasons for the same will be
discussed in that order.
There are very few published reports describing the expression of these
genes after chronic administration of E2 in these animals. A recent study reported
that diethyl stilbesterol (DES), another potent estrogen, when administered intraperitoneally for four days continuously at a bolus dose of 50 mg/kg body weight,
does not modify the expression of either phase I or phase II enzymes in the ACI
rat mammary on the fifth day (Green et al., 2007). However, this differs
considerably from the model in this study, which involves systemic delivery of
constant levels of estradiol (Shull et al., 1997; Ravoori et al., 2007). Kauffman
and coworkers have studied the activities of phase II enzymes after chronic E2
treatment in ACI rat liver and brain (Sanchez et al., 2003; Stakhiv et al., 2006).
They report that E2 increases the protien and activity levels of hepatic GST and
NADPH-quinone reductase in rat treated for 6 weeks with a 2 mg of E2 delivered
via a cholesterol pellet (Sanchez et al., 2003). E2 has a similar effect also on the
brain enzymes (Stakhiv et al., 2006). The primary consideration in the
interpretation of the results of this study is that, other variables such as effect of
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E2 on other organ systems (pituitary, liver etc.,) have not been considered and
the mammary is taken as a unitary tissue. However, these variables and their
possible effect on estrogen-induced mammary carcinogenesis and its prevention
are discussed in Chapter 5.
Another important detail that must be taken into account while interpreting
results in the current study is the proliferation of mammary epithelial cells in
response to E2 treatment. At 6 weeks after treatment, the E2-treated mammary
largely consists of proliferating cells of epithelial origin; however, sham-treated
tissue consists of a much higher percentage of stromal cells. As reported from
our laboratory the proliferative index markers PCNA and Ki-67 are significantly
increased after 90 days of E2 treatment and the representative tissue sections
also indicate differences in the predominant cell types (Ravoori et al., 2007 in
press; Chapter 3, Figure 3.9). Thus, the differences in the cell composition
between untreated and treated rats may potentially confound the results as these
analyses were done from total tissue RNA.
The serum level of estradiol was 35 pg/ml in sham-treated and 194 pg/ml
in estradiol-treated animals, 6 weeks after treatment (Chapter 3). This 5.5 fold
increase in the estradiol level is reflected both in the increased proliferation of the
mammary tissue as well as the significant down-regulation of ERα and
concomitant up-regulation of PGR. The levels of ERß were not affected. E2
down-regulates ERα and up-regulates PGR in the epithelial cells of a normal
mammary gland (Mauvais-Jarvis et al., 1986b; Shyamala et al., 2002). Induction
of mammary tumors in ERKO/Wnt-1 mice by E2 shows that ER is not necessary
for E2-induced carcinogenesis (Devanesan et al., 2001). In cultured human
epithelial cells, synthetic progesterones antagonize the proliferative action of E2
via PGR (Mauvais-Jarvis et al., 1986a; Poulin et al., 1989). Although, the upregulation of PGR occurs at 6 weeks and to a lesser extent 18 weeks, but is
absent at 24 weeks, the down-regulation of ERα continues till 24 weeks,
suggesting three things- i) the mammary tumors in the ACI rats may arise in an
ER-independent fashion; ii) that epithelial cells are acclimated to high circulating
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estradiol levels and hence do not show consistent up-regulation of PGR, which is
a downstream effect of estradiol treatment more apparent at an early time point;
and iii) that these tumors may not be responsive to the negative-regulation, if
there is any, by progesterone .
Although most transcriptional regulation of estradiol is attributed to its
action via the estrogen receptor, it can also act in an ER-independent fashion
(Coleman & Smith, 2001). The transcription of CYP1A1 and 1B1 are regulated by
both the ER and the aryl hydrocarbon receptor (AhR) (Hollenberg, 2002;
Tsuchiya et al., 2005; Sissung et al., 2006). However, there is a disjunction
between these 2 pathways, depending on the clonality of the breast cancer cell
line, with the 2 pathways acting in a mutually exclusive manner (Angus et al.,
1999). Both CYP1A1 and 1B1 can be induced by 2,3,7,8-tetrachlorodibenzo-pdioxin (TCDD) depending on the ER status of the cell (Angus et al., 1999). This
suggests that ER may not directly control the expression of these enzymes.
Moreover, the expression of these enzymes has been attributed to specific cell
types, i.e., the epithelial cells versus the stromal fibroblasts. It is reported that
CYP1B1 expression is constitutively higher in the rat mammary stroma; whereas
CYP1A1 can be induced beyond basal levels only in the epithelial cells by PAHs
and TCDD (Christou et al., 1995). Thus, in these animals where the epithelial-cell
proliferation in response to estradiol treatment has occurred, the levels of total
tissue CYP1B1 in the untreated animals may reflect the stromal compartment
and are thus higher than E2 treatment. Contrarily, CYP1A1, that is predominantly
present in the epithelial cells is up-regulated by over 40-fold, suggesting that this
up-regulation is reflective of both the cell population and the treatment.
These phase I enzymes are predominantly responsible for the conversion
of estradiol to genotoxic metabolites (Russo & Russo, 2004). It has been
reported that ACI rat mammary is highly susceptible to mutations after intramammillary administration of estrogen-3-4-quinone (Mailander et al., 2006). Also
DNA damage caused by different catechol estrogens has been extensively
reported by Cavalieri and coworkers (Cavalieri et al., 2006). However, all these
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reports have looked at short term, bolus dose of moderately toxic doses of these
agents (Li et al., 2004; Mailander et al., 2006). However, the status of these
metabolites in E2- induced mammary cancer is not known and the metabolites
themselves do not cause mammary tumors in ACI rats (Turan et al., 2004). Both
CYP1A1 and CYP1B1 can convert E2 to 4E2, although CYP1B1 predominates
(Liehr, 2000; Cribb et al., 2006). Nevertheless, 15-20% of the E2 metabolite
produced by CYP1A1 is 4E2 (Liehr, 2000). Thus, there is a possibility to generate
genotoxic metabolites in the presence of excess E2 and high expression of
CYP1A1, since CYP1A1 partially catalyses the production of 4E2. Further, in
comparison to CYP1A1, COMT and GST, enzymes whose substrates are
CYP1A1 products, are only up-regulated by 2- to 4-fold indicating an imbalance.
Another interesting finding is the up-regulation of 17ßHSD7 by estradiol.
This enzyme has high specificity for the conversion of estrone to estradiol in the
mammary, suggesting that estradiol may influence in-situ estrogen synthesis.
However, 17HSD7 expression is affected by both E2 and prolactin in the rat
corpus luteum (Duan et al., 1997; Risk et al., 2005), and E2 induces pituitary
prolactinomas in this model (Shull et al., 1997). Thus, either E2 may directly
influence the expression of 17ßHSD7 or this may be a downstream effect of
increased prolactin secretion. This enzyme is involved in the conversion of
estrone to estradiol, however, the expression of aromatase which forms estrone
from androgen precursors, is almost undetectable in the mammary tissue of the
ACI rat (data not shown), which raises questions about the role that 17ßHSD7
plays in in-situ estrogen synthesis.
It has been shown in MCF-7 cells and rat uterine lieyomieomas that
physiological levels of E2 down-regulates COMT expression via ER pathways
(Xie et al., 1999; Al-Hendy & Salama, 2006). In this study, there is a slight overexpression of COMT at all time points. The results with respect to GSTA1 are
corroborated by published reports of increase in GST activity in ACI rat liver and
brain after 6 weeks of E2 treatment (Sanchez et al., 2003; Stakhiv et al., 2006).
However, these studies look at GST activities and thus do not differentiate
106

between GST isozymes. Nevertheless, the induction of P450 enzymes by their
substrates is well documented (Hollenberg, 2002; Hayes et al., 2005). Thus, the
over-expression of both COMT and GSTA1 may be in response to the presence
of catechol-estrogen metabolites. It has been shown that the conjugation of E2metabolites can be isoform specific (Abel et al., 2004). Also, the 2 families of
cytosolic GSTs Alpha (A) and Mu (M) heterodimerise and have similar substrate
specificities for xenobiotic metabolism (Hayes et al., 2005). These factors may
influence the differential regulation of GSTA1 and GSTM1 by E2.
In this study, neither berries nor ellagic acid show a differential expression
of the steroid receptors, suggesting that the berry phytochemicals act by
alternate mechanisms to bring about their specific effects. The berries show a
significant effect with regard to the regulation of CYP1A1. CYP1A1 expression is
controlled by AhR/ARNT signaling and whether berries mediate their effect by
affecting this signaling pathway is not clear. However, the significant reduction in
the CYP1A1 expression may translate to lower levels of harmful estradiol
metabolites, as discussed above. Further, proof that berries may affect
metabolite formation is evident from the CYP1B1 data, berries and ellagic acid
down-regulate CYP1B1 expression much more than estradiol, suggesting that
there may be a net reduction in harmful estradiol metabolites in the mammary
epithelial cells of animals fed berries and ellagic acid. This is substantiated by the
effect of both berries and ellagic acid on COMT expression at 18 weeks. The
significant reduction in the COMT expression may be due to the constant
suppression in the production of catechol-estrogen metabolites by sustained
down-regulation of CYP1A1 and to a lesser extent of CYP1B1. Ellagic acid does
not alter CYP1A1 expression, suggesting that it differs from other berry
phytochemicals (anthocyanins) in its mechanism of action. Several reports
suggest that dietary ellagic acid does not alter the expression of hepatic CYP1A1
(Barch et al., 1994; Ahn et al., 1996). However, it inhibits CYP1A1 activity both in
vitro and in vivo (Barch et al., 1994). Further, ellagic acid also increases the
expression of hepatic quinone reductase, which is involved in the removal of
harmful estrogen-metabolites via an antioxidant response element (Barch &
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Rundhaugen, 1994). This enzyme is down-regulated after E2-treatment in ACI rat
mammary (Montano et al., 2006). It is not known whether berries or ellagic acid
up-regulate its expression in the mammary. Berries and ellagic acid also downregulate 17ßHSD7, which may further reduce in-situ E2 formation.
Collectively, these data suggest that CYP1A1 may play a major role in the
generation of harmful catechol-estrogen metabolites in E2-induced mammary
tumorigenesis and that intervention by berries significantly reduce the formation
of these metabolites and thus lead to prevention of mammary tumors. Ellagic
acid acts via a different mechanism to reduce the levels of these metabolites.
These results have to be further confirmed by analyzing the levels of various E2metabolites in the mammary tissue. Also, the differential effects of both E2 and
the chemopreventive agents on the various cell types must be delineated to
understand cell-type specific actions of these agents.
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Figure 4.1. A simplified schematic representation of in-situ estrogen metabolism
and steroid receptor signaling in the ACI rat mammary.
Pink arrows indicate binding and purple arrows indicate transcriptional regulation
by nuclear factors. Up regulation is represented by
represented by

,

,

and down regulation is

for ellagic acid and berries respectively. Regulations that

need to investigated are marked with a “?”. 17ß-HSD7 – 17ß-hydroxy steroid
dehydrogenase, type 7; CYP1A1/1B1- Cytochrome P450 1A1/1B1; COMTCatecho-O-methyl transferase; GSTA1/M1- Glutathione-S-transeferase.

109

Relative fold change

Phase I enzymes - 6 weeks
4

17ß-HSD7

a

3

Sham-Control diet

2

b

b a,b

E2-Control diet
E2-Blueberry diet
E2-Black raspberry diet

1

E2-Ellagic acid diet

Relative fold change

0

50
40

CYP1A1

a

1.5

a

1.0

30
20
10

CYP1B1

b
0.5

b

a
a

0

a,b

0.0

Figure 4.2. Effect of diets supplemented with indicated agents on the expression
of genes involved in phase I estrogen metabolism, 6 weeks after estrogen
treatment.
The relative fold change is expressed as mean ± SEM of n=6 per group. The
results were compared using one way-ANOVA, followed by Tukey’s test and the
significant differences (p<0.05) are denoted as follows: a - significantly different
from sham treated on control diet; b - significantly different from E2 treated on
control diet. 17ßHSD- 17ß hydroxy streroid dehydrogenase, type 7.
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Figure 4.3. Effect of diets supplemented with indicated agents on the expression
of genes involved in phase I estrogen metabolism, 18 weeks after estrogen
treatment.
The relative fold change is expressed as mean ± SEM of n=6 per group. The
results were compared using one way-ANOVA, followed by Tukey’s test and the
significant differences (p<0.05) are denoted as follows: a - significantly different
from sham treated on control diet; b - significantly different from E2 treated on
control diet. 17ßHSD- 17ß hydroxy streroid dehydrogenase, type 7.
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Figure 4.4. Effect of diets supplemented with indicated agents on the expression
of genes involved in phase I estrogen metabolism, 6 weeks after estrogen
treatment.
The relative fold change is expressed as mean ± SEM of n=6 per group. The
results were compared using one way-ANOVA, followed by Tukey’s test and the
significant differences (p<0.05) are denoted as follows: a - significantly different
from sham treated on control diet; b - significantly different from E2 treated on
control diet. 17ßHSD- 17ß hydroxy streroid dehydrogenase, type 7.
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Figure 4.5. Effect of diets supplemented with indicated agents on the expression
of genes involved in phase II estrogen metabolism, 6 weeks after estrogen
treatment.
The relative fold change is expressed as mean ± SEM of n=6 per group. The
results were compared using one way-ANOVA, followed by Tukey’s test and the
significant differences (p<0.05) are denoted as follows: a - significantly different
from sham treated on control diet; b - significantly different from E2 treated on
control
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Figure 4.6. Effect of diets supplemented with indicated agents on the expression
of genes involved in phase II estrogen metabolism, 18 weeks after estrogen
treatment.
The relative fold change is expressed as mean ± SEM of n=6 per group. The
results were compared using one way-ANOVA, followed by Tukey’s test and the
significant differences (p<0.05) are denoted as follows: a - significantly different
from sham treated on control diet; b - significantly different from E2 treated on
control
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Figure 4.7. Effect of diets supplemented with indicated agents on the expression
of genes involved in phase II estrogen metabolism, 24 weeks after estrogen
treatment.
The relative fold change is expressed as mean ± SEM of n=6 per group. The
results were compared using one way-ANOVA, followed by Tukey’s test and the
significant differences (p<0.05) are denoted as follows: a - significantly different
from sham treated on control diet; b - significantly different from E2 treated on
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Figure 4.8. Effect of diets supplemented with indicated agents on the expression
of steroid receptors, 6 weeks after estrogen treatment.
The relative fold change is expressed as mean ± SEM of n=6 per group. The
results were compared using one way-ANOVA, followed by Tukey’s test and the
significant differences (p<0.05) are denoted as follows: a - significantly different
from sham treated on control diet; b - significantly different from E2 treated on
control diet. ER- Estrogen receptors; PGR- Progesterone receptor.
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Figure 4.9. Effect of diets supplemented with indicated agents on the expression
of steroid receptors, 18 weeks after estrogen treatment.
The relative fold change is expressed as mean ± SEM of n=6 per group. The
results were compared using one way-ANOVA, followed by Tukey’s test and the
significant differences (p<0.05) are denoted as follows: a - significantly different
from sham treated on control diet; b - significantly different from E2 treated on
control diet. ER- Estrogen receptors; PGR- Progesterone receptor.
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Figure 4.10. Effect of diets supplemented with indicated agents on the
expression of steroid receptors, 24 weeks after estrogen treatment.
The relative fold change is expressed as mean ± SEM of n=6 per group. The
results were compared using one way-ANOVA, followed by Tukey’s test and the
significant differences (p<0.05) are denoted as follows: a - significantly different
from sham treated on control diet; b - significantly different from E2 treated on
control diet. ER- Estrogen receptors; PGR- Progesterone receptor.
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Relative fold change

Variations in phase I enzymes over time
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Figure 4.11. Variations in phase I enzymes of estrogen metabolism at different
time points after estrogen treatment.
Six animals were randomized in to each group and were euthanized 6, 18 and 24
weeks after 17ß-estradiol implantation. RNA from the whole mammary tissue
was analyzed for gene expression using quantitative real-time PCR. 17ßHSD17ß hydroxy streroid dehydrogenase.
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Relative fold change

Variations in phase II enzymes over time
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Figure 4.12. Variations in phase II enzymes of estrogen metabolism at different
time points after estrogen treatment.
Six animals were randomized in to each group and were euthanized 6, 18 and 24
weeks after 17ß-estradiol implantation. RNA from the whole mammary tissue
was analyzed for gene expression using quantitative real-time PCR. COMTCatechol-O-methyl transferase; GST-Glutathione-S-transferase.

120

Relative fold change

Variations in steroid receptors over time
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Figure 4.13. Variations in steroid receptor expression at different time points
after estrogen treatment.
Six animals were randomized in to each group and were euthanized 6, 18 and 24
weeks after 17ß-estradiol implantation. RNA from the whole mammary tissue
was analyzed for gene expression using quantitative real-time PCR. EREstrogen receptors; PGR- Progesterone receptor.
.
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Table 4.1. Experimental protocol – effect of berries and ellagic acid on estrogen
metabolism during estrogen-induced mammary tumorigenesis in ACI rats.

1
2
3
4
5

Group
Treatment
description
SH-CD
Sham
E2-CD
E2-BB
17ß-estradiol
E2-BRB
E2-EA

Intervention
Control diet
Control diet
2.5% (w/w) blueberries
2.5% (w/w) black raspberry
400 ppm ellagic acid

Eighteen animals were randomized in to each group and fed respective diets
from 2 weeks prior to estrogen treatment until the end of the study. Six animals
from each group were euthanized at 6, 18 and 24 weeks after estrogen
treatment.
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Table 4.2. Primer sequences for quantitative real-time PCR.

Gene

Forward

Reverse

17ß HSD

5' - CTTTATCCTGATTCGGGAACTG - 3'

5' - GTCCTCAAGACTGAAGTTAGA C - 3'

CYP1A1

5' - TGGAGACCTTCCGACATTCAT - 3'

5' - GGGATATAGAAG CCATTCAGACTT G - 3'

CYP1B1

5' - AACCCAGAGGACTTTGATCCG - 3'

5' - CGTCGTTTGCCCACTGAAAA - 3'

COMT

5' - GGATGCAGTGATTCGGGAGTA - 3'

5' - GCAGCGTAGTCAGGGTTCATCT - 3'

GSTA1

5' - CCAGCCTTCTGACCTCTTTCC - 3'

5' - TCTTCGATTTGTTTTGCATCCA - 3'

GSTM1

5' - TCTTGACCAGTACCACATTTTTGA G - 3'

5' - TCGAAAATATAGGTGTTGAGAGGTAGTG - 3'

ERα

5' - GGCACATGAGTAACAAAGGCA - 3'

5' - GGCATGAAGACGATGAGCAT - 3'

ERß

5' - CTCCTTTAGCGACCCATTGC - 3'

5' - CTCCCACTAAGCTTCCTCTTCAGT - 3'

PGR

5' - TCACAACGCTTCTATCAACTTACAAA - 3'

5' - GGCAGCAATAACTTCAGACATCA - 3'

ß-Actin

5' – GCCAACCGTGAAAAGATGAC - 3'

5' - ACCCTCATAGATGGGCACAG - 3'

Primers were designed using Primer Express® software across exon boundary
for the following genes: 17ßHSD7- 17ß hydroxyl steroid dehydrogenase
7;CYP1A1-Cytochrome P450 1A1; CYP1B1-Cytochrome P450 1B1; COMTCatechol-O-methyl transferase; GSTA1- Glutathione-S-transferase A1; GSTM1Glutathione-S-transferase M1; ERα-Estrogen receptor α; ERß-Estogen receptor
ß; PGR- Progesterone receptor.
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Table 4.3. Effect of diets supplemented with indicated agents with on expression
of genes involved in estrogen metabolism and signaling in ACI rat mammary 6
weeks after estrogen treatment
Gene
17ßHSD
CYP1A1
CYP1B1
COMT
GSTA1
GSTM1
ERα
ERß
PGR

Fold Change SH-CD
(mean ± SEM) (n=3)
0.73±0.2
Relative
Absolute
Relative
Absolute
Relative
Absolute
Relative
Absolute
Relative
Absolute
Relative
Absolute
Relative
Absolute
Relative
Absolute
Relative
Absolute

E2-BB
(n=6)
1.3±0.1

E2-BRB
(n=6)
1.6±0.2

E2-EA
(n=5)
1.5±0.4

1
4.8a
0.75±0.09 36.7±5.5

1.8b
16.3±2.5

2.2b
9.2±1.8

2.5a,b
42.7±5.7

1
1.1±0.1
1
0.9±0.04

48a
0.6±0.2
1.8↓
1.8±0.1

21b
0.1±0.01
11a↓
1.4±0.05

12b
0.1±0.01
11a,b↓
1.2±0.1

56a
0.3±0.1
3.6a↓
1.5±0.4

1
0.7±0.2

2
5.2±2.0

0.7
2.6±0.3

1.3
2.3±0.6

1.6
3.1±1.0

1
0.6±0.2

1
0.7±0.2

7.4
0.2±0.03
3a↓
0.05±0.01
10a↓
0.9±0.2

3.7
0.2±0.01
3a↓
0.05±0.004
10a↓
1.3±0.2

3.3
0.1±0.01
6a↓
0.05±0.001
10a↓
1.5±0.3

4.4
0.2±0.02
3a↓
0.06±0.01
8.3a↓
1.5±0.3

1
2.3±0.8

1.3
8.3±0.9

1.8
8.8±0.6

2.1
8.6±0.8

2.1
12.3±3.1

1

3.6

3.8

3.7

5.3a

1
0.5±0.3

E2-CD
(n=6)
3.5±0.4

Female ACI rats were treated with subcutaneous sham implants (SH-CD) or
those containing 27 mg 17ß-estradiol (E2-CD) and fed control diet or diets
supplemented with 2.5% w/w blueberries (E2-BB); black raspberries (E2-BRB) or
400 ppm ellagic acid (E2-EA) and euthanized 6 weeks after treatment. Relative
and absolute gene expression changes were calculated as described in materials
and methods. The results were compared using one way-ANOVA, followed by
Tukey’s test and the significant differences (p<0.05) are denoted as follows: a significantly different from sham treated on control diet (SH-CD); b - significantly
different from E2 treated on control diet (E2-CD). Down–regulation of genes is
denoted by a downward arrow (↓)
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Table 4.4. Effect of diets supplemented with indicated agents with on expression
of genes involved in estrogen metabolism and signaling in ACI rat mammary 18
weeks after estrogen treatment
Gene
17ßHSD
CYP1A1
CYP1B1
COMT
GSTA1
GSTM1
ERα
ERß
PGR

Fold Change
(mean ± SEM)
Relative
Absolute
Relative
Absolute
Relative
Absolute
Relative
Absolute
Relative
Absolute
Relative
Absolute
Relative
Absolute
Relative
Absolute
Relative
Absolute

SH-CD
(n=5)
2.1±10.5
1
0.98±0.2
1
0.8±0.1
1
2.3±0.4
1
1.6±0.2
1
1.3±0.2
1
2.1±0.4
1
2.1±0.8

E2-CD
(n=6)
3.3±10.4
1.6
14.4±2.5
14.7a
0.1±0.01
8a↓
4.4±0.4
1.9a
3.6±0.4
2.25a
0.4±0.04
3.25a↓
0.5±0.05
4.2a↓
2.5±0.4

E2-BB
(n=6)
3.0±0.2
1.4
6.8±0.7
6.9
0.1±0.01
8a↓
2.8±0.1
1.2b↓
4.1±0.4
2.6a
0.5±0.1
2.6a↓
0.5±0.02
4.2a↓
2.6±0.7

E2-BRB
(n=6)
3.3±0.2
1.6
16.1±2.3
16.4a
0.2±0.04
4a↓
2.6±0.1
1.1b↓
5.1±0.4
3.2a,b
0.5±0.1
2.6a↓
0.5±0.05
4.2a↓
2.6±0.4

E2-EA
(n=6)
2.9±0.4
1.4
17.5±2.7
17.8a
±0.02
8a↓
1.9±0.3
1.1b↓
2.8±0.3
1.75
0.4±0.1
3.25a↓
0.4±0.05
5.2a↓
1.6±0.2

1
1.2±0.4
1

1.2
4.6±0.3
3.8a

1.2
4.2±0.4
3.5a

1.2
4.5±0.3
3.75a

1.3
2.2±0.1
1.8b

Female ACI rats were treated with subcutaneous sham implants (SH-CD) or
those containing 27 mg 17ß-estradiol (E2-CD) and fed control diet or diets
supplemented with 2.5% w/w blueberries (E2-BB); black raspberries (E2-BRB) or
400 ppm ellagic acid (E2-EA) and euthanized 18 weeks after treatment. Relative
and absolute gene expression changes were calculated as described in materials
and methods. The results were compared using one way-ANOVA, followed by
Tukey’s test and the significant differences (p<0.05) are denoted as follows: a significantly different from sham treated on control diet (SH-CD); b - significantly
different from E2 treated on control diet (E2-CD). Down–regulation of genes is
denoted by a downward arrow (↓)
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Table 4.5. Effect of diets supplemented with indicated agents with on expression
of genes involved in estrogen metabolism and signaling in ACI rat mammary 24
weeks after estrogen treatment

Gene
17ßHSD
CYP1A1
CYP1B1
COMT
GSTA1
GSTM1
ERα
ERß
PGR

Fold Change
(mean ± SEM)
Relative
Absolute
Relative
Absolute
Relative
Absolute
Relative
Absolute
Relative
Absolute
Relative
Absolute
Relative
Absolute
Relative
Absolute
Relative
Absolute

SH-CD
(n=5)
0.9±0.1

E2-CD
(n=6)
1.5±0.1

E2-BB
(n=5)
1.5±0.2

E2-BRB
(n=6)
1.4±0.2

E2-EA
(n=6)
1.8±0.1

1
0.9±0.1

1.6
7.3±1.2

1.6
6.5±1.3

1.5
2.9±0.4

1.9a
4.2±0.6

1
0.8±0.03
1
0.9±0.1

8.1a
0.09±0.01
4a↓
1.7±0.1

7.2a
0.14±0.01
5.7a↓
1.5±0.2

3.2b
0.1±0.01
8a↓
1.1±0.3

4.6a
0.1±0.01
8a↓
1.6±0.1

1
0.3±0.2

1.8a
0.4±0.1

1.6
0.3±0.1

1.2
0.3±0.1

1.7
0.3±0.05

1
0.8±0.1

1
0.8±0.2

1
0.3±0.02
2.6a-↓
0.1±0.01
10.5a↓
0.4±0.1
1.75↓
1.7±0.1

1
0.3±0.05
2.6a-↓
0.08±0.01
13.1a↓
0.4±0.1
1.75↓
1.3±0.2

1
0.3±0.02
2.6a-↓
0.09±0.01
11.6a↓
0.3±0.1
2.3↓
1.4±0.2

1
0.3±0.03
2.6a-↓
0.1±0.01
10.5a↓
0.6±0.1
1.2↓
1.6±0.2

1

2.1

1.6

1.75

2

1
1.05±0.2
1
0.7±0.1

Female ACI rats were treated with subcutaneous sham implants (SH-CD) or
those containing 27 mg 17ß-estradiol (E2-CD) and fed control diet or diets
supplemented with 2.5% w/w blueberries (E2-BB); black raspberries (E2-BRB) or
400 ppm ellagic acid (E2-EA) and euthanized 24 weeks after treatment. Relative
and absolute gene expression changes were calculated as described in materials
and methods. The results were compared using one way-ANOVA, followed by
Tukey’s test and the significant differences (p<0.05) are denoted as follows: a significantly different from sham treated on control diet (SH-CD); b - significantly
different from E2 treated on control diet (E2-CD). Down–regulation of genes is
denoted by a downward arrow (↓).
Copyright © Harini Sankaran Aiyer, 2007
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Chapter Five: General Discussion and Conclusions

Millions of women in the world are chronically exposed to 17ß-estradiol.
This hormone is highly important for regular development but also increases the
risk for breast cancer.

Since women cannot be completely protected from

exposure, prevention is an effective course of action to reduce the incidence of
breast cancer. Many of the current treatment strategies evolve around this
concept. Currently, tamoxifen therapy is the standard care for women who are at
a high risk for breast cancer and involves 5 years of preventive therapy (Morrow
& Jordan, 2000). However, this therapy does not come without costs, several
side effects of tamoxifen treatment include increased incidence of blood clots,
depression in some cases, endometrial cancer in post-menopausal women, etc,.
(Reviewed by Anthony, Williams and Dunn, 2001). Raloxifene, another selective
estrogen receptor mediator (SERM) is effective in reducing certain risks
associated with tamoxifen therapy is poorly bioavailable and rapidly excreted
from the body (Jordan, 2007). Thus, the search for an ideal estrogen receptor
modulator that will have the nuero- and osteo-protective effects of estrogen and
also prevent cancer in estrogen-target tissues has become the holy grail of
modern breast cancer prevention research.
Most cells in the human body possess an estrogen receptor (ER) and the
gene transcription function of estrogen was thought to be mediated via its
interaction with this receptor. However, it is now documented that estradiol can
act via non receptor-mediated pathways to cause changes in cell function
(Reviewed in Coleman and Smith, 2001). Ideally, a SERM can interact with any
or all of these pathways and its structural similarity to estrogen determine the
interactions. Phytonutrients, such as polyphenols can act on several different
pathways that overlap with estrogen/steroid signaling, such as MAPK, PKC, etc.,
suggesting that they may posses SERM effects beyond actions on the classic ER
(Reviewed by Rushmore and Tony Kong, 2002).
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The estradiol-induced mammary tumor in ACI rats provides an apt in vivo
testing system to test several SERMs. Although most breast cancer drugs have
traditionally been tested against 7,12, dimethyl benze[a]anthacene-induced
mammary tumors, estrogen-induction causes several signal transduction
cascades that can only occur in the presence of excess estradiol. In fact, the
results from studies presented herein show that ERα in the mammary is downregulated by estradiol treatment. Thus E2-induced mammary carcinogenicity in
the ACI rat may involve non receptor-mediated action of E2. Tamoxifen (40 mg in
subcutaneous cholesterol pellets) completely abrogates E2-induced tumors in
ACI rats (Li et al., 2002b). However, this study showed significant increases in
various ERα isoforms by immunohistochemical detection and increased levels of
both progesterone receptor (PGR) isoforms (Li et al., 2002b). The contrasting
results with respect to ERα expression can be attributed to difference in the
methods of detection (qRTPCR versus immunohistochemistry) and the presence
and differential regulation of different isoforms of ER, which may be detected at
the protein level but not at the mRNA level unless specific primers are designed
for this purpose.
The importance of other organ systems, such as the liver must also be
taken in to account when analyzing the mechanisms by which E2 induces
mammary tumors. For example, both phenobarbitol (PB) and clofibrate (CF)
when administered together with E2 have differential effects on the metabolism of
E2 in the liver (Mesia-Vela et al., 2004; Mesia-Vela et al., 2006). PB acts
synergistically with E2, while CF antagonizes its action. Further, PB effectively
reduces the mammary tumor burden. This may be due to the direct effect of PB
on E2 metabolism in the mammary or via indirect mechanisms due to changes
caused in other organs such as liver as reported (Mesia-Vela et al., 2006).
Studying the effects of berries and ellagic acid on hepatic metabolism may yield
more clues about the mechanisms by which these agents prevent mammary
tumors. Indeed, both red raspberry and ellagic acid when provided via the diet
have significant effects on hepatic gene transcription in CD-1 mice (Chapter 2). It
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remains to be seen whether similar and additional effects are present in the ACI
rats also.
The mechanisms involved in E2-induced mammary tumorigenesis in ACI
rats are complex. Some mechanisms have been elucidated, while several others
need to be clarified. Foremost, ACI rats are the only rat strain that is completely
susceptible to E2-induced mammary tumors (Dunning et al., 1953; Shepel &
Gould, 1999). In all of the prevention studies, the serum E2 levels do not differ
between the different groups, suggesting that preventive agents can act without
altering the circulating E2 levels (Li et al., 2002b; Mesia-Vela et al., 2006);
Chapter 3). Further, prolactin is considered to play a major role in the
development of these tumors (Holtzman et al., 1981). Tamoxifen, which
abrogates mammary tumors in female ACI rats, also reduces pituitary tumors
and serum prolactin levels in male ACI rats treated continuously with E2 (Lyle et
al., 1984). The effect of tamoxifen on the pituitary of female rats has not been
reported, however, it significantly reduces the uterine wet-weight (Li et al.,
2002b), which could be an indicator of and effect on both direct estrogen action
and effect via pituitary hormones. Further evidence for the role of pituitary in
mammary tumor development can be garnered from estradiol-dose response
studies done in our laboratory and also presented in this work. When the dose of
E2 is reduced 3-fold (from 27 mg to 9 mg), the tumor burden as well as tumor
number increase (Chapter 3, Tables 3.5 and 3.6; Ravoori et al., 2007). There is a
striking correlation between the ratios of serum E2 and plasma prolactin levels
between the two doses. When the E2 dose is reduced by 3-fold, the circulating E2
and prolactin levels fall by 2.8- and 2.5- fold respectively at 12 weeks and by
about 1.7 fold at termination of the study (Ravoori et al., 2007).This correlation
exemplifies the direct effect of E2 on prolactin levels. It is unclear whether
prolactin impedes or improves tumor development since lower levels of prolactin,
caused by lowering the E2 dose, increases tumor burden but the absence of a
prolactin response results in non-induction of mammary tumors (Holtzman et al.,
1981). However, the effect of complete inhibition of prolactinomas with
bromocriptine or tamoxifen in female ACI rats and subsequent effects on
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mammary tumor incidence has not been reported. Further investigation is
warranted to elucidate the exact role of prolactin in mammary cancer
development in ACI rats.
There is collective evidence that black raspberry, blueberry and ellagic
acid may prevent E2–induced tumorigenesis by interrupting the effects of
pituitary. First, the pituitary wet weights are slightly, but insignificantly reduced by
dietary intervention at both doses of E2 treatment (Chapter 3, Tables 3.5 and
3.6). Second, compared to sham treatment, the combined wet weight of ovary
and uterus increased significantly in animals treated with 27 mg E2 for 24 weeks
(870 ± 50 mg versus 620 ± 80 mg) (p<0.01). This increase in tissue weight was
significantly reduced after dietary intervention (p<0.05; blueberry diet – 650 ± 18;
black raspberry diet- 600 ± 77; ellagic acid diet – 650 ± 42 mg). These results
are similar in trend but not in magnitude to tamoxifen treatment (Li et al., 2002; S.
Li, personal communication).

Moreover, all dietary interventions significantly

offset the overexpression of 17ßHSD, a gene known to be controlled by prolactin,
at 6 weeks (Duan et al., 1997). However, the levels of prolactin must be
measured in the serum of animals on the supplemented group to confirm this
notion. Taken together, these facts suggest that both berries and ellagic acid
may act as SERMs, but at a much lower capacity compared to a classic
antiestrogen like tamoxifen. Further studies are required to confirm the SERM
effects of these dietary agents in the various estrogen-responsive organs of the
ACI rat including the pituitary, ovary, uterus, adrenal and the mammary.
The contribution of the classic ER pathway in the mammary tissue of
these animals is not clear since E2 treatment seems to down-regulate ERα
expression by more than 10 fold beginning at 6 weeks until the end of the
experiment. Furthermore, it is not known if estradiol signals through other
pathways to cause molecular changes. Also, estradiol is known to cause
chromosomal instability and c-myc amplification in these rats (Li et al., 2002a). It
is not clear yet if the interventions affect any of these pathways and further
studies are required to elucidate this.
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Estrogen is an endobiotic. The importance of estrogen metabolism in the
causation of breast cancer has been understood based on several data.
Polymorphisms in one or more genes that are involved in estradiol metabolism
increase the carrier’s risk of breast cancer (Thompson & Ambrosone, 2000;
Gallicchio et al., 2006). Also, there is an imbalance in the metabolic profile
between cancer-free and cancer-prone women. In addition, tumor tissue contains
higher levels of metabolites such as 4-hydroxy estradiol (4E2) than in the
surrounding normal tissue (Reviewed by Liehr, 2000). To support these
observations, laboratory studies have also proven the pro-carcinogenic effects of
4E2 (Liehr et al., 1986; Russo et al., 2002), suggesting that 4E2 and CYP1B1
may play the major role in E2-induced carcinogenesis. However, CYP1A1 is a
mixed function oxygenase, which can form both 2E2 and 4E2 (Cribb et al., 2006).
It is clear from our findings that berries consistently offset E2-induced up
regulation of CYP1A1 and of CYP1B1 at 6 weeks only. Ellagic acid, however, is
effective against CYP1B1 only. The transcriptional regulation of these enzymes
is controlled by various nuclear receptors via interaction with antioxidant
response elements (AREs) and electrophile response elements (EpREs)
(Reviewed by Honkakoshi & Negishi, 2000 and by Hollenberg, 2002). Further
research is required to elucidate the exact mechanisms of action of berry
phytochemicals. Studies suggest that ellagic acid decreases the activity of
hepatic CYP1A1 without increasing its expression and also increases the
expression and activity of quinone reductase, an enzyme involved in phase II
metabolism of estrogen metabolites (Barch & Rundhaugen, 1994; Barch et al.,
1994; Ahn et al., 1996). The effect of both berry anthocyanins and ellagic acid on
quinone reductase in the mammary must be investigated. Berries vary widely in
their distribution of anthocyanins and ellagic acid. Of the berries tested, blueberry
has a wider spectrum of anthocyanins but in lower quantities, while black
raspberry contains predominantly one anthocyanin but in much higher amounts
(Wu et al., 2006). Whether these differences influence their preventive efficacy is
not known. This can be tested by using bilberries, which are high in anthocyanin
content and also have a wide variety of polymers (Wu et al., 2006).
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To summarize the results presented herein, 17ß-estradiol induces
mammary tumors in ACI rats when administered alone. Berries and ellagic acid
prevent the growth of these tumors by up to 70%. Also, these agents favorably
alter estrogen-metabolizing enzymes in the mammary tissue. Although, there are
some differences in the trends between berries versus ellagic acid 2 conclusions
seem to emerge - 1) both berries act via similar mechanisms; 2) ellagic acid acts
via a different mechanism to produce the same protective effect. Further, both
berries and ellagic acid effectively reduce baseline DNA damage and induce
DNA repair enzyme expression, in the liver of CD-1 mice. In addition, ellagic acid
is the most effective polyphenol to reduce 4E2-induced DNA damage in vitro.
Taken together these results suggest that both berries and ellagic acid may act
via multiple mechanisms to prevent E2–induced mammary tumorigenesis.
The most important conclusion of this thesis is that regardless of the
mechanisms involved, both berries and ellagic acid beneficially influence
mammary tumorigenesis in ACI rats. This provides evidence that a low dose of
whole foods can be used in the prevention of breast cancer as effectively as
relatively higher dose of a pure constituent. Although no reduction in mammary
tumor incidence was seen in this investigation, the better quality of life in berryand ellagic acid-fed animals, as evidenced by reduced mortality, weight loss etc.,
and significant reductions in tumor burden, provide strong support for the use of
these agents as an adjuvant alongside traditional modes of cancer therapy. The
safety and applicability of such an intervention is being tested for esophageal
cancer (Kresty et al., 2006). Preclinical studies looking at the interaction between
classic prevention therapy such as tamoxifen and berries are required before
proceeding to clinical trials. Also, studies assessing whether berries, berry
anthocyanins and ellagic acid will antagonize the adverse actions of tamoxifen
must be conducted. Nevertheless, the use of berries as an adjuvant in breast
cancer prevention holds much promise.
Copyright © Harini Sankaran Aiyer, 2007
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APPENDIX
List of abbreviations
2-AAF
2-E2
3-MC
4-E2
8-oxodG
17ßHSD
ACI
B[a]P
BMI
CF
COMT
COX-2
CYP
DB[a,l]P
DCIS
DMBA
DMSO
DNL3
E2
EGCG
ERα
ERß
ERCC5
ERK
ERKO/wnt-1
GST
HAA
HNE
HRT
Lob 1
MAPK
MAPKK
MDA
NADP
NFқB
NMU
PAH
PB
PCNA
PEI
PGR
PhIP
PKC
PRL

2-acetylaminofluorine
2-hydroxy estradiol
3-methylcholantherene
4-hydroxy estradiol
8-oxo-2’ deoxy Guanosine
17-ß-hydroxysteroid dehydrogenase
August-Copenhagen-Irish-hooded
Benzo[a]pyrene
Body Mass Index
Clofibrate
Catechol-O-methyl transferase
Cyclooxygenase -2
Cytochrome P450
Dibenzo[a,l]pyrene
Ductal carcinoma in situ
7,12-dimethylbenz(a)antharcene
Dimethyl sulphoxide
DNA ligase 3
17ß-estradiol
Epigallocatechin gallate
Estrogen receptor Alpha
Estrogen receptor Beta
Excision repair cross complementation group 5
Extracellular signal related kinase
Estrogen receptor knock-out/wnt
Glutathione-S-transferase
Heterocyclic aromatic amines
Hydroxy nonenal
Hormone replacement therapy
Lobules type 1
Mitogen activated protein kinase
MAP kinase kinase
Malodialdehyde
Nicaonitamide dinucleotide phosphate
Nuclear factor қ B
1-methyl-1-nitrosourea
Polycyclic aromatic hydrocarbons
Phenobarbital
Proliferating Cell Nuclear Antigen
Polyethyleneinimine
Progesterone Receptor
2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine
Protein Kinase C
Prolactin
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ROS
SD
SERM
SOD
TCDD
TDLU
TLC
TST
VEGF
XPA

Reactive Oxygen Species
Sprague Dawley
Selective estrogen receptor modulator
Superoxide Dismutase
2,3,7,8-tetrachlorodibenzo-p-dioxin
Terminal Ductal Lobular Unit
Thin layer chromatography
Thiosulphate sulphur transferase
Vascular endothelial growth factor
Xeroderma Pigmentosum group A complementing protein
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